Document:

exv10w62

Exhibit 10.62

     *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

LICENSE AND SETTLEMENT AGREEMENT

     THIS LICENSE AND SETTLEMENT AGREEMENT (this “Agreement”) dated as of November 26, 2008 (the
“Effective Date”) is entered into between Medicis Pharmaceutical Corporation, a Delaware
corporation with offices located at 7720 North Dobson Road, Scottsdale, Arizona 85256 on behalf of
itself and its Affiliates (collectively, “Medicis”), and Impax Laboratories, Inc., a Delaware
corporation with offices located at 30831 Huntwood Avenue, Hayward, California 94544 on behalf of
itself and its Affiliates (collectively, “Impax”).

     WHEREAS, Medicis is the owner of the Patent Rights (as defined below);

     WHEREAS, Medicis and Impax have entered into that certain Joint Development Agreement of even
date herewith (the “Joint Development Agreement”) pursuant to which Impax is conducting research
and development for a derivative of Medicis’ product marketed and sold under the trademark
Solodyn®; and

     WHEREAS, in partial consideration for Impax’s efforts under the Joint Development Agreement,
Impax desires to receive a license under the Patent Rights and Medicis desires to grant to Impax a
license under the Patent Rights, all on the terms and conditions of this Agreement.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:

     1. DEFINITIONS.

          1.1 “Affiliate” means, with respect to any entity, any other entity that directly or
indirectly controls, is controlled by, or is under common control with, such entity. An entity
shall be regarded as in control of another entity if it owns, or directly or indirectly controls,
at least fifty percent (50%) of the voting stock or other ownership interest of the other entity,
or if it directly or indirectly possesses the power to direct or cause the direction of the
management and policies of the other entity by any means whatsoever.

          1.2 “AG Term” shall have the meaning set forth in Section 2.2.2.

          1.3 “AG Trigger” means ***.

          1.4 “ANDA” means an Abbreviated New Drug Application and any supplements thereto.

          1.5 “Business Day” means any day other than a Saturday, Sunday or a day on which banks in
Arizona are authorized or required by law to close.

 

 

          1.6 “Confidential Information” means all non-public materials, information and data concerning
the disclosing party and its operations that is disclosed by the disclosing party to the receiving
party pursuant to the Confidentiality Agreement, this Agreement, the Joint Development Agreement or
the Distribution Agreement, orally or in written, electronic or tangible form, or otherwise
obtained by the receiving party through observation or examination of the disclosing party’s
operations. Confidential Information includes, but is not limited to, information about the
disclosing party’s financial condition and projections; business, marketing or strategic plans;
sales information, customer lists; price lists; databases; trade secrets; product prototypes and
designs; techniques, formulae, algorithms and other non-public process information.
Notwithstanding the foregoing, Confidential Information of a party shall not include that portion
of such materials, information and data that, and only to the extent, the recipient can establish
by written documentation: (a) is known to the recipient as evidenced by its written records before
receipt thereof from the disclosing party, (b) is disclosed to the recipient free of
confidentiality obligations by a Third Party who has the right to make such disclosure without
obligations of confidentiality, (c) is or becomes part of the public domain through no fault of the
recipient, or (d) the recipient can reasonably establish is independently developed by persons on
behalf of recipient without the use of the information disclosed by the disclosing party.

          1.7 “Confidentiality Agreement” means ***

          1.8 “Control” means with respect to any material, information, or intellectual property right,
that a party (a) owns such material, information, or intellectual property right, or (b) has a
license or right to use such material, information, or intellectual property right, in each case
with the ability to grant to the other party access, a right to use, a license, or a sublicense (as
applicable) to such material, information, or intellectual property right on the terms and
conditions set forth herein, without violating the terms of any agreement or other arrangement with
any Third Party.

          1.9 “Cost of Sales” means, on a per Existing Product or per Generic Subsequent Product basis
and for a given calendar quarter, the sum of the Manufacturing Costs and Distribution and Sales
Costs for such Existing Product or Generic Subsequent Product sold during such calendar quarter.

          1.10 “Distribution Agreement” shall have the meaning set forth in Section 2.2.1.

          1.11 “Distribution and Sales Costs” means, on a per Existing Product or per Generic Subsequent
Product basis and for a given calendar quarter, (a) an amount equal to *** and (b) an amount equal
***; provided, however, that any of the foregoing costs that are included within the definition of
“Distribution and Sales Costs” may not be deducted again when calculating Net Sales.

          1.12 “Existing Product” means any product (a) that is a Generic Equivalent of the Solodyn
Products, (b) that is sold pursuant to ANDA #90-024 under Impax’s control, and (c) the making,
using, selling or importation is covered by one or more Valid Claims.

2

 

          1.13 “FDA” means the United States Food and Drug Administration or any successor entity
thereto.

          1.14 “Generic Equivalent” means ***.

          1.15 “Generic Subsequent Product” means the Medicis-authorized generically labeled version of
the Subsequent Product.

          1.16 “Grantback Patents” means (a) ***, (b) all divisions, continuations,
continuations-in-part, that claim priority to, or common priority with, the patent applications
described in clause (a) above or the patent applications that resulted in the patents described in
clause (a) above, and (c) all patents that have issued or in the future issue from any of the
foregoing patent applications, including utility, model and design patents and certificates of
invention, together with any reissues, renewals, extensions or additions thereto.

          1.17 “Gross Profit” means, with respect to all Existing Products or all Generic Subsequent
Products in a calendar quarter, the remainder, if any, that results from Net Sales of Existing
Products or Generic Subsequent Products, as applicable, in the Territory minus the Cost of Sales of
Existing Products or Generic Subsequent Products, as applicable. With respect to a product, to the
extent such remainder is a negative number, such loss shall not be due and owing by Medicis, but
Impax shall have the right to offset such loss against any positive remainder for such product only
in the immediately succeeding calendar quarter.

          1.18 “License Trigger” means the first to occur of any of the following:

               1.18.1 ***; or

               1.18.2 ***; or

               1.18.3 ***; or

               1.18.4 the third (3rd) anniversary of the Effective Date.

***

          1.19 “Manufacturing Costs” means (each of the following to be determined in accordance with
GAAP applied in a manner consistent with past practices of Impax) (a) the delivered cost to Impax
of a Existing Product or Generic Subsequent Product for use or sale in the Territory if a Third Party
(or Medicis) is the manufacturer of such Existing Product or
Generic Subsequent Product provided that such Existing Product or Generic Subsequent Product is
provided pursuant to an arms-length and commercially reasonable agreement, or (b) where Impax is
itself the manufacturer, the sum of Materials Costs, labor costs, Overhead and Freight And Taxes
incurred by Impax to produce such Existing Product for use or sale in the Territory, including the
costs of rejected or failed batches of such Existing Product. As used herein, “Materials Cost”
means Impax’s procurement costs for (i) raw materials (both active and inactive ingredients), and
(ii) packaging, labeling and storing materials, incurred in connection with the manufacture,
testing, labeling, purchasing and distribution of such Existing Product; “Overhead” means all
indirect costs of manufacturing such Existing Product including, without

3

 

limitation, insurance, inspection, testing, quality control and quality assurance, depreciation, maintenance and repair
costs, all as determined in accordance with the U.S. GAAP, and “Freight And Taxes” means all
insurance, freight and shipping charges, import taxes and duties and similar taxes and duties
levied by the United States or other government entity with jurisdiction, and port and loading
charges, all to the extent not already deducted under Distribution and Sales Costs.

          1.20 “Net Sales” means, with respect to a given Existing Product or Generic Subsequent
Product, the aggregate gross price of such Existing Products or Generic Subsequent Products
received by Impax or its sublicensees from unaffiliated retailers, distributors or other customers,
less the sum of the following items, all of which must directly relate to the sale and distribution
of such Existing Products or Generic Subsequent Products and be determined in accordance with GAAP
applied in a manner consistent with past practices of Impax: (a) returns, credits, rebates,
discounts, allowances, promotional payments, free goods, chargebacks and other price reduction
programs customary to the trade or required by law, (b) sales, valued-added and other taxes, (c)
***, (d) customs duties, surcharges and other governmental charges, (e) ***, and (f) ***. Sales
between or among Impax and its Affiliates shall not be included in Net Sales unless Impax or its
Affiliates are the end user of the Existing Products or Generic Subsequent Products.

          1.21 “Patent Rights” means (a) the patents and patent applications listed on Exhibit A to this
Agreement, (b) ***; (c) all divisions, continuations, continuations-in-part, that claim priority
to, or common priority with, the patent applications described in clauses (a) and (b) above or the
patent applications that resulted in the patents described in clauses (a) and (b) above, and (d)
all patents that have issued or in the future issue from any of the foregoing patent applications,
including utility, model and design patents and certificates of invention, together with any
reissues, renewals, extensions or additions thereto.

          1.22 “Product” means any product for which the making, using, selling or importation is
covered by one or more claims of the Patent Rights.

          1.23 “Solodyn Products” means the Solodyn products listed on Exhibit B, as such products are
marketed and sold by Medicis as of the Effective Date in the Territory.

          1.24 “Solodyn Product Patents” means (a) all patents and patent applications in the Territory
Controlled by Impax as of the Effective Date that claim or cover a Solodyn Product or the
manufacture or use of a Solodyn Product, (b) all divisions, continuations and continuations-in-part (solely to the extent directed to subject matter disclosed in a patent
or patent application described in clause (a) above) that (i) claim priority to, or common priority
with, the patent applications described in clause (a) above or the patent applications that
resulted in the patents described in clause (a) above and (ii) claim or cover a Solodyn Product or
the manufacture or use of a Solodyn Product, and (c) all patents that issue after the Effective
Date from any of the foregoing patent applications, including utility, model and design patents and
certificates of invention, together with any reissues, renewals, extensions or additions thereto,
***.

          1.25 “Subsequent Product” means ***.

4

 

          1.26 “Territory” means the United States of America including its territories and possessions.

          1.27 “Third Party” means any person or entity other than Medicis or Impax.

          1.28 “Trade” shall have the meaning set forth in Section 2.2.1.

          1.29 “Valid Claim” means ***.

     2. LICENSES; RELEASES.

          2.1 License Grant for Existing Product.

               2.1.1 Effective only upon the occurrence of the License Trigger, Medicis hereby grants to
Impax a non-exclusive, non-transferable (except as permitted in Section 8.6) license (without the
right to grant sublicenses except to have made Existing Products on behalf of Impax) under the
Patent Rights to make, have made, use, offer for sale, sell and import inside the Territory
Existing Products.

               2.1.2 Until the occurrence of the License Trigger, Impax shall not, and shall not directly or
indirectly encourage or assist any Third Party to, develop and/or commercialize any Existing
Products in the Territory; provided, however, that Impax shall not be subject to the foregoing
restriction at any time when there is no Valid Claim in the Territory claiming the Existing Product
or its manufacture or use.

               2.1.3 Nothing in this Agreement shall be construed as creating an obligation, express or
implied, on Medicis to supply any Existing Product to Impax. Impax shall be solely responsible for
manufacturing, or having manufactured, its supply of Existing Product.

               2.1.4 ***.

               2.1.5 Each party shall promptly notify the other in writing of the occurrence of the License
Trigger. In addition, Medicis shall keep Impax apprised of the status of material developments
that affect when the License Trigger occurs, that Impax would not otherwise be aware of ***. Impax
shall notify Medicis in writing at least five (5) days before Impax initiates commercialization of
the Existing Product if the date of such initiation is anticipated to be before the License
Trigger.

          2.2 Subsequent Products; Distribution Agreement.

               2.2.1 With respect to the Subsequent Product, and effective only upon the occurrence of the AG
Trigger, Medicis hereby appoints Impax as its exclusive distributor of the Generic Subsequent
Product in the Territory and authorizes Impax, under the Patent Rights, to market the Generic
Subsequent Product solely to wholesalers, distributors, retailers, mail order, managed care, and
group purchasing organizations (collectively, the “Trade”) in the Territory, pursuant to a separate
distribution and supply agreement (the “Distribution Agreement”) to be entered into between Impax
and Medicis.

5

 

               2.2.2 Commencing on the Effective Date, the parties shall negotiate in good faith the terms of
and enter into the Distribution Agreement, which will contain the following provisions:

	 	•	 	Unless earlier terminated for cause or by Impax for convenience, the term of any such
appointment of Impax as the exclusive distributor of the Generic Subsequent Product shall extend
from the AG Trigger and remain in effect until *** (the “AG Term”).
	 
	 	•	 	Medicis will supply (either itself or through its Third Party manufacturer) Impax its
requirements in the Territory for the Generic Subsequent Product in finished form; on such
forecasting, invoicing, shipment, delivery, inspection and payment terms as are agreed upon by the
parties and set forth in the Distribution Agreement; including, without limitation ***;
	 
	 	•	 	Medicis will manufacture the Generic Subsequent Product in accordance with cGMPs and
the specifications, at a transfer price equal to ***;
	 
	 	•	 	In exchange for such appointment, Impax agrees that during the term of the
Distribution Agreement, and in the case of termination of the Distribution Agreement for any reason
for a period of *** after such termination, not to market or launch a Generic Equivalent of the
Subsequent Product in the Territory, or sell to any Third Party any Generic Subsequent Product if
it has reason to believe that such person intends to sell such product inside the Territory; the
Distribution Agreement will not include any other limitations on development, submission of
regulatory filings or commercialization by Impax;
	 
	 	•	 	Impax shall pay to Medicis *** of all Gross Profit resulting from sales of the Generic
Subsequent Product, on a quarterly basis, on such terms as are agreed by the parties;
	 
	 	•	 	To the extent that Medicis is required to pay a royalty or other payment to a Third
Party with respect to a license to such Third Party’s intellectual property to distribute the
Generic Subsequent Product in the Territory, the parties will deduct such payment from the
calculation of Gross Profit ***;
	 
	 	•	 	Medicis and Impax will each indemnify the other for third party claims arising from
their actions under the Distribution Agreement and breaches of representations and warranties; and
	 
	 	•	 	such other terms as the parties may agree and as are commercially reasonable and usual
and customary for agreements of such type.

               2.2.3 If the parties do not agree upon the terms of the Distribution Agreement within sixty
(60) days of the Effective Date, then either party may, by written notification to the other party,
submit the matter to binding “baseball” arbitration to determine the terms of the Distribution
Agreement as follows. Promptly following receipt of such notice, the parties shall meet and
discuss in good faith and agree on an arbitrator to resolve the issue, which

6

 

arbitrator shall be neutral and independent of both parties, shall have significant experience and expertise in
distribution and supply agreements in the generic pharmaceutical industry, and shall have some
experience in mediating or arbitrating issues relating to such agreements. If the parties cannot
agree on such arbitrator within thirty (30) days of request by a party for arbitration, then such
arbitrator shall be appointed by the American Arbitration Association, which arbitrator must meet
the foregoing criteria. Within fifteen (15) days after an arbitrator is selected (or appointed, as
the case may be), each party will deliver to both the arbitrator and the other party a detailed
written proposal setting forth its proposed terms for the Distribution Agreement, which terms shall
not conflict with the terms set forth in Section 2.2.2 (the “Proposed Terms” of the party) and a
memorandum (the “Support Memorandum”) in support thereof, not exceeding ten (10) pages in length.
The parties will also provide the arbitrator a copy of this Agreement, as may be amended at such
time. Within fifteen (15) days after receipt of the other party’s Proposed Terms and Support
Memorandum, each party may submit to the arbitrator (with a copy to the other party) a response to
the other party’s Support Memorandum, such response not exceeding five (5) pages in length.
Neither party may have any other communications (either written or oral) with the arbitrator other
than for the sole purpose of engaging the arbitrator or as expressly permitted in this Section
2.2.3; provided that, the arbitrator may convene a hearing if the arbitrator so chooses to ask
questions of the parties and hear oral argument and discussion regarding each party’s Proposed
Terms. Within sixty (60) days after the arbitrator’s appointment, the arbitrator will select one
of the two Proposed Terms (without modification) provided by the parties that he or she believes is
most consistent with the intention underlying and agreed principles set forth in this Agreement and
most accurately reflects industry norms for a transaction of this type. The decision of the
arbitrator shall be final, binding, and unappealable and the parties shall promptly enter into a
Distribution Agreement having the terms set forth in the Proposed Terms selected by the arbitrator.
For clarity, the arbitrator must select as the only method to determine the terms of the
Distribution Agreement one of the two sets of Proposed Terms, and may not combine elements of both
Proposed Terms or take any other action.

          2.3 Grantbacks.

               2.3.1 Impax hereby grants to Medicis a perpetual, royalty-free, fully-paid up,
non-transferable (except as provided in Section 8.6), non-exclusive license (with the right to
grant sublicenses through multiple tiers) under the Grantback Patents to make, have made, use,
offer for sale, sell and import Products in the Territory.

               2.3.2 Impax hereby grants to Medicis a perpetual, royalty-free, fully-paid up,
non-transferable (except as provided in Section 8.6), non-exclusive license (with the right to
grant sublicenses through multiple tiers) under the Solodyn Product Patents to make, have made,
use, offer for sale, sell and import Solodyn Products in the Territory.

          2.4 Validity of Patent Rights. Impax hereby admits that the following Patent Rights
claims are valid and enforceable: (a) all claims that are in the patents listed on Exhibit A that
issued prior to the Effective Date (not taking into account any claim amendments filed, before, on
or after the Effective Date, pursuant to a reexamination or reissuance proceeding) and (b) all
claims listed on Exhibit C from pending patent applications, as such claims were worded as of the
Effective Date and as they may be modified during prosecution of the underlying application
following the Effective Date, but only to the extent they remain substantially similar.

7

 

Impax hereby admits that the making, using, offering to sell, selling, and/or importation into the United
States of Impax’s product that is to be sold pursuant to Impax’s ANDA #90-024 is covered by one or
more claims of United States Patent No. 5,908,838 (not taking into account any claim amendments
filed, before, on or after the Effective Date, pursuant to a reexamination or reissuance
proceeding) under 35 U.S.C. § 271. The foregoing admission shall be binding on Impax and
admissible against Impax in any dispute or litigation between the parties regarding the Patent
Rights, and Impax will not challenge any such admission. Impax shall not receive any rights under
this Agreement, and Medicis shall retain the sole right, to prepare, prosecute, maintain and
enforce the Patent Rights.

          2.5 No Implied Licenses. Except as explicitly set forth in this Agreement, neither
party grants to the other party under its patents or other intellectual property any license,
express or implied. Impax shall not use Medicis’ name or any Medicis trademarks (including without
limitation Solodyn®) in connection with the marketing, promotion or sale of any products without
the prior written consent of Medicis in each instance.

          2.6 Releases. Impax has appealed the holding of the United States District Court for
the Northern District of California, Civil Action No. 3:2008cv00253 to the United States Court of
Appeals for the Federal Circuit, Appeal No. 2008-1373 (collectively, the “Action”), in which Impax
challenges the district court’s dismissal of Impax’s declaratory judgment action regarding the
invalidity and noninfringement of certain of the Patent Rights. In consideration of the mutual
covenants herein and in the Joint Dismissal Agreement attached hereto as Exhibit D and incorporated
herein by reference Impax hereby releases and agrees to release Medicis from all claims arising out
of the Action. Upon the Effective Date, Impax and Medicis shall cause to be completed, executed
and filed with the Federal Circuit a stipulated dismissal with prejudice of the Action, in the form
of the Joint Dismissal Agreement attached hereto as Exhibit D, and to seek entry of such order and
judgment by such Court.

     3. FINANCIAL CONSIDERATIONS.

          3.1 Profit Sharing.

               3.1.1 With respect to the Existing Products, and subject to the terms and conditions of this
Agreement, commencing on the date Impax begins selling an Existing Product, within sixty (60) days
following the end of each calendar quarter thereafter, Impax shall pay to Medicis *** of all Gross
Profit accrued during such calendar quarter and arising from Net Sales of such Existing Products
during such quarter. Medicis’ right to receive a share of the Gross Profit under this Section
3.1.1 shall expire upon ***.

               3.1.2 Impax shall not (a) have any obligation to pay any amounts pursuant to Section 3.1.1, or
(b) be subject to the restrictions under Section 2.1.2, in each case if there is no Valid Claim in
the Territory at the time of sale of an Existing Product; provided, however, that if there is at
the time of such sale a pending patent application in the Patent Rights in the Territory with a
published claim which covers such Existing Product or its manufacture or use and a patent
subsequently issues in the Territory from such patent application that contains such claim or a
claim that is substantially similar to such claim, then Impax shall pay Medicis within thirty (30)
days of receipt from Medicis of written notice of the issuance of such patent,

8

 

an amount equal to ***. If there is no Valid Claim in the Territory and a patent subsequently issues in the Territory
from a patent application within the Patent Rights and there is a dispute between the parties
regarding whether at least one such subsequently issued claim covers the Existing Product or its
manufacture or use then upon the submission of a written request of either party to the other
party, such dispute shall be resolved exclusively by binding arbitration before a single
arbitrator, conducted in accordance with the rules of arbitration of the American Arbitration
Association for commercial disputes (the “Rules”), except to the extent that such Rules are
inconsistent with this Agreement. Each party shall select one independent, neutral representative,
and shall notify the other party of its selection of such representative within ten (10) business
days after the written request for binding arbitration. The two (2) representatives selected by
the parties shall then mutually select, within twenty (20) business days, in accordance with the
Rules, an independent, neutral arbitrator who is admitted to practice before the United States
Patent and Trademark office and has at least ten (10) years of experience as a patent attorney in
the biotechnology or pharmaceuticals field. The arbitrator shall resolve such dispute in
accordance with this Agreement and the substantive rules of law (but not the rules of procedure or
conflicts of laws) that would be applied by a federal court sitting in Arizona, provided that Impax
shall have to demonstrate to the arbitrator by clear and convincing evidence that the Existing
Product or its manufacture or use is not covered by at least one Valid Claim. The arbitrator shall
use best efforts to issue a final decision within ninety (90) days after being selected. The final
decision of the arbitrator shall be final and binding upon the parties, solely for purposes of
determining Impax’s obligations under Section 2.1.2 and/or Impax’s obligations to pay royalties
under Section 3.1.1, but such decision shall have no force or effect on any other person in
accordance with 35 U.S.C. 294 or with respect to any products other than the Existing Products. If
Impax breaches its obligations under this Section or Section 2.1.2, Impax hereby agrees that in any
subsequent litigation between the parties Impax shall be subject to a rebuttable presumption of
willful infringement. All negotiations pursuant to this Section 3.1.2 and the arbitration
proceeding and decision of the arbitrator shall be confidential, treated as a compromise and
settlement negotiation for purposes of applicable rules of evidence, including without limitation Rule 408 of the Federal Rules of Evidence. The parties agree that they
shall share equally the cost of the arbitration filing and hearing fees, and the cost of the
representative and the arbitrator. Each party shall bear its own attorneys’ and expert fees and
all associated costs and expenses. ***.

               3.1.3 Each payment made under this Section 3.1 shall be accompanied by a written report
stating the number and description of all Existing Products sold in the Territory during the
relevant calendar quarter; a detailed breakdown of the Cost of Sales associated therewith; the
gross sales associated therewith; the calculation of Net Sales thereon, including without
limitation the amount of any deduction provided for in the definition of Net Sales; and the
calculation of Gross Profits therefrom.

          3.2 Taxes. Impax shall be responsible for and may withhold from payments made to
Medicis under this Agreement any taxes required to be withheld by Impax under applicable law.
Accordingly, if any such taxes are levied on such payments due hereunder (“Withholding Taxes”),
Impax shall (i) deduct the Withholding Taxes from the payment amount, (ii) pay all applicable
Withholding Taxes to the proper taxing authority, and (iii) send evidence of the obligation
together with proof of tax payment to Medicis within sixty (60) days following that tax payment.

9

 

          3.3 Audit Rights. On no less than five (5) business days notice from Medicis, Impax
shall make all such records, books of account, information and data concerning (i) its sales of
Existing Products pursuant to this Agreement; and (ii) its manufacture of any Existing Products, or
(iii) to the extent in its possession, the manufacture of Existing Products on behalf of Impax by
its Third Party contract manufacturer, in each case available for inspection during normal business
hours by an independent auditor selected by Medicis and reasonably acceptable to Impax for the
purpose of an audit to determine the accuracy of the reports delivered and amounts paid by Impax
pursuant to Section 3.1; provided that Medicis may not request such inspection more than once in
any calendar year unless a discrepancy has been identified by Medicis and such audit shall be
limited to records, books of account, information and data pertaining to payments made pursuant to
Section 3.1 during the preceding three years. Upon reasonable belief of discrepancy or dispute,
Medicis’ external auditors shall be entitled to take copies or extracts from such records, books of
account, information and data (but only to the extent related to the contractual obligations set
out in this Agreement) during any review or audit. Prior to the initiation of any audit pursuant
to this Section 3.3, the external auditor shall sign a confidentiality agreement with Impax
providing that, as between the external auditor and Impax, such records, books of account,
information and data shall be treated as Confidential Information of Impax but may be disclosed to
Medicis solely to the extent necessary to document a discrepancy in any reports delivered and
amounts paid by Impax pursuant to Section 3.1. Medicis shall be solely responsible for its costs
in making any such audit, unless Medicis identifies a discrepancy in favor of Impax in the
calculation of the share of Gross Profit paid to Medicis under this Agreement in any calendar year
from those properly payable for that calendar year of five percent (5%) or greater, in which event
Impax shall be solely responsible for the reasonable cost of such audit and pay Medicis any
underpayment. All information disclosed by Impax pursuant to this Section shall be deemed
Confidential Information of Impax.

     4. TERM AND TERMINATION.

          4.1 Term. Subject to Section 4.2, this Agreement shall expire on the expiration of
the later to occur of (a) the last to expire of the Patent Rights and (b) the expiration of all
payment obligations of Impax to Medicis hereunder; provided, however, that if there are no Valid
Claims existing in the Territory, but there are at such time pending patent applications in the
Patent Rights in the Territory, then subject to the terms and conditions of this Agreement, the
term of this Agreement shall continue for the pendency of such pending applications. The
expiration of this Agreement shall not cause the expiration of the Distribution Agreement and vice
versa.

          4.2 Termination for Cause. Either party may terminate this Agreement upon or after
the material breach of any material provision of this Agreement by the other party if the other
party has not cured such breach within thirty (30) days after receipt of express written notice
thereof by the non-breaching party. Any termination of this Agreement by Medicis for material
uncured breach by Impax shall give rise to a right of Medicis also to terminate the Distribution
Agreement; however, any breach of the Distribution Agreement will not be automatically deemed a
breach of this Agreement.

          4.3 Effect of Expiration or Termination. Expiration or termination of this Agreement
shall not relieve the parties of any obligation accruing prior to such expiration or

10

 

termination, and the provisions of Sections 2.3, 2.4, 2.6, 3.3 (until expiration of the three (3) year period
set forth therein), 4.3, 5, 7 and 8 shall survive the expiration or termination of this Agreement.

     5. CONFIDENTIALITY. 

          5.1 Confidentiality. Until the last to expire of this Agreement, the Joint
Development Agreement or the Distribution Agreement, and for a period of five (5) years following
the expiration or earlier termination hereof or thereof, except with respect to any Confidential
Information constituting a trade secret in which case the receiving party’s obligation continues in
perpetuity, provided such receiving party has been informed as to the status of such Confidential
Information as a trade secret, each party shall maintain in confidence all Confidential Information
disclosed by the other party (including all Confidential Information disclosed under the
Confidentiality Agreement), and shall not use, grant the use of or disclose to any Third Party the
Confidential Information of the other party other than as expressly permitted hereby. Each party
shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other
party’s Confidential Information.

          5.2 Permitted Disclosures. Either party may disclose Confidential Information of the
disclosing party (a) on a need-to-know basis, to such party’s directors, officers and employees to
the extent such disclosure is reasonably necessary in connection with such party’s activities as
expressly authorized by this Agreement, and (b) to those agents and consultants, and contract
manufacturers who need to know such information to accomplish the purposes of this Agreement
(collectively, “Permitted Recipients”); provided such Permitted Recipients are bound to maintain
such Confidential Information in confidence at least to the same extent as set forth in Section
5.1.

          5.3 Litigation and Governmental Disclosure. Each party may disclose Confidential
Information of the other party to the extent such disclosure is reasonably necessary for
prosecuting or defending litigation, complying with a court order or applicable law, governmental
regulations or investigation, provided that if a party is required by law or regulation to make any
such disclosure of the other party’s Confidential Information it will give reasonable advance
notice to the other party of such disclosure requirement and will use good faith efforts to assist
such other party to secure a protective order or confidential treatment of such Confidential
Information required to be disclosed.

          5.4 Limitation of Disclosure. The parties agree that, except as otherwise may be
required by applicable laws, regulations, rules or orders, including without limitation the rules
and regulations promulgated by the United States Securities and Exchange Commission, or any
regulations of any national securities exchange, and except as may be authorized in Section 5.5, no
information concerning this Agreement and the transactions contemplated herein shall be made public
by either party without the prior written consent of the other.

          5.5 Publicity. Neither party shall make any publicity releases, interviews or other
non-confidential dissemination of information concerning this Agreement or its terms, or either
party’s performance hereunder, to communication media, financial analysts or others without the
prior written approval of the other party, which approval shall not be unreasonably

11

 

withheld, delayed or conditioned. Notwithstanding anything to the contrary in this Agreement, the parties
understand and agree that either party, may, if so required, disclose some or all of the
information included in this Agreement or other Confidential Information of the other party (a) in
order to comply with its obligations under the law, including the United States Securities Act of
1933 and the United States Securities Exchange Act of 1934; (b) in order to comply with the listing
standards or agreements of any national or international securities exchange or The NASDAQ Stock
Market or New York Stock Exchange or other similar laws of a governmental authority; (c) to respond
to an inquiry of a governmental authority or regulatory authority as required by law; or (d) in a
judicial, administrative or arbitration proceeding. In any such event the party making such
disclosure shall (i) provide the other party with as much advance notice as reasonably practicable
of the required disclosure, (ii) cooperate with the other party in any attempt to prevent or limit
the disclosure, and (iii) limit any disclosure to the specific purpose at issue. In connection
with any filing of a copy of this Agreement with the Securities and Exchange Commission, the filing
party shall endeavor to obtain confidential treatment of economic and trade secret information, and
shall keep the other party informed as the planned filing (including, but not limited to providing
the other party with the proposed filing reasonably in advance of making the planned filing) and
consider the requests of the other party regarding such confidential treatment.

     6. REPRESENTATIONS AND WARRANTIES.

          6.1 Representations.

               6.1.1 Each party hereby represents and warrants to the other party that (a) the person
executing this Agreement is authorized to execute this Agreement; (b) this Agreement is legal and
valid and the obligations binding upon such party are enforceable by their terms; and (c) the
execution, delivery and performance of this Agreement does not conflict with any agreement, instrument or understanding, oral or written, to which such party may be
bound, nor violate any law or regulation of any court, governmental body or administrative or other
agency having jurisdiction over it.

               6.1.2 Medicis hereby represents and warrants to Impax that, as of the Effective Date, ***.

          6.2 Compliance with Law. Impax shall comply with all applicable laws and regulations
with respect to obtaining regulatory approval for the sale of Existing Products and its
manufacture, sale and commercialization of Existing Products.

          6.3 Disclaimer of Warranties. Except for those warranties set forth in Section 6.1,
neither party makes any warranty, written, oral, express or implied, with respect to this
Agreement. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED
WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT HEREBY ARE
DISCLAIMED BY BOTH PARTIES.

          6.4 Limitation of Liability. WITH THE EXCEPTION OF DAMAGES RESULTING FROM A PARTY’S
BREACH OF ITS CONFIDENTIALITY OBLIGATIONS

12

 

UNDER THIS AGREEMENT OR ITS OBLIGATIONS UNDER SECTION 7 (INDEMNIFICATION), OR A BREACH BY IMPAX OF SECTION 2.1.2 OR SECTION 2.4, UNDER NO CIRCUMSTANCES
SHALL EITHER PARTY BE LIABLE FOR LOSS OF USE OR PROFITS OR OTHER COLLATERAL, SPECIAL,
CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, WHETHER SUCH
CLAIMS ARE FOUNDED IN TORT OR CONTRACT.

          6.5 Equitable Relief. Impax acknowledges and agrees that the obligations and
undertakings of Impax pursuant to Sections 2.1.2 and 2.4 of this Agreement are reasonable and
necessary to protect the legitimate interests of Medicis, that Medicis would not have entered into
this Agreement in the absence of such provisions, and that Impax’s breach or threatened breach or
failure to comply with such Sections 2.1.2 or 2.4 shall cause Medicis significant and irreparable
harm, the amount of which shall be extremely difficult to estimate and ascertain, and for which
money damages shall not be adequate. Impax further acknowledges and agrees that Medicis shall have
the right to apply to any court of competent jurisdiction for an injunction order restraining any
breach or threatened breach of Sections 2.1.2 or 2.4 of this Agreement and specifically enforcing
the terms and provisions of such Sections of this Agreement, without the necessity of posting any
bond or security or giving Impax an opportunity to cure, in addition to seeking any other remedy
available to Medicis in law or equity. Impax agrees that it shall not challenge any of the
foregoing acknowledgements and agreements concerning injunctive relief in any proceeding brought by
Medicis.

     7. INDEMNIFICATION.

          7.1 Impax Indemnification. Impax shall indemnify, defend and hold harmless Medicis,
its directors, managers, members, officers, employees, authorized subcontractors and agents
(collectively the “Medicis Indemnified Parties”) from and against any and all liabilities, obligations, penalties, judgments, disbursements of any kind and nature, losses, damages,
costs and expenses (including, without limitation, reasonable attorney’s fees and costs)
(collectively, “Losses”) incurred as a result of any claims, demands, actions or other proceedings
by a Third Party against an Indemnified Party to the extent arising out of (a) Impax’s manufacture
or sale of any Existing Product pursuant to this Agreement; or (b) Impax’s breach of any
representation, warranty or covenant under this Agreement, except to the extent that such Losses
arise out of Medicis’ breach of any representation, warranty or covenant under this Agreement.

          7.2 Medicis Indemnification. Medicis shall indemnify, defend and hold harmless Impax,
its directors, managers, members, officers, employees, authorized subcontractors and agents
(collectively the “Impax Indemnified Parties”) from and against any and all Losses incurred as a
result of any claims, demands, actions or other proceedings by a Third Party against an Indemnified
Party to the extent arising out of Medicis’ breach of any representation, warranty or covenant
under this Agreement, except to the extent that such Losses arise out of Impax’s breach of any
representation, warranty or covenant under this Agreement.

          7.3 Obligations. A party which intends to claim indemnification under this Section 7
(the “Indemnified Party”) shall promptly notify the other party (the “Indemnifying Party”) in
writing of any claim, demand, action, or other proceeding in respect of which the Indemnified Party
intends to claim such indemnification; provided, however, that failure to

13

 

provide such notice within a reasonable period of time shall not relieve the Indemnifying Party of any of its
obligations hereunder except to the extent the Indemnifying Party is prejudiced by such failure.
The Indemnified Party shall permit the Indemnifying Party, at its discretion, to settle any such
action, claim or other matter. Notwithstanding the foregoing, the Indemnifying Party shall not
enter into any settlement that would adversely affect the Indemnified Party’s rights hereunder, or
impose any obligations on the Indemnified Party in addition to those set forth herein, in order for
it to exercise such rights, without the Indemnified Party’s prior written consent, which shall not
be unreasonably withheld or delayed. No such action, claim or other matter shall be settled
without the prior written consent of the Indemnifying Party, which shall not be unreasonably
withheld or delayed. The Indemnified Party shall reasonably cooperate with the Indemnifying Party
and its legal representatives in the investigation and defense of any claim, demand, action, or
other proceeding covered by the indemnification obligations of this Section 7. The Indemnified
Party shall have the right, but not the obligation, to be represented in such defense by counsel of
its own selection and at its own expense.

     8. GENERAL PROVISIONS.

          8.1 Notices. All notices hereunder shall be delivered by facsimile (confirmed by
overnight delivery), or by overnight delivery with a reputable overnight delivery service, to the
following address of the respective parties:

	 	 	 
	          If to Medicis:

	 	Medicis Pharmaceutical Corporation

7720 North Dobson Road

Scottsdale, Arizona 85256

Attn: Chief Executive Officer

Facsimile: 480-291-5163
	 
	 	 
	          with a copy to:

	 	Medicis Pharmaceutical Corporation

7720 North Dobson Road

Scottsdale, Arizona 85256

Attn: General Counsel

Facsimile: 480-291-5163
	 
	 	 
	          If to Impax:

	 	Impax Laboratories, Inc.

30831 Huntwood Avenue

Hayward, California 94544

Attn: President, Generics Division

Facsimile: 510-471-1595
	 
	 	 
	          With a copy to:

	 	Impax Laboratories, Inc.

30831 Huntwood Avenue

Hayward, California 94544

Attn: Legal Department

Facsimile: 510-476-2092

     Notices shall be effective on the day of receipt. A party may change its address listed above
by notice to the other party given in accordance with this Section 8.1.

14

 

          8.2 Entire Agreement. The parties hereto acknowledge that this Agreement sets forth
the entire agreement and understanding of the parties and supersedes all prior written or oral
agreements or understandings with respect to the subject matter hereof. No modification of any of
the terms of this Agreement, or any amendments thereto, shall be deemed to be valid unless in
writing and signed by an authorized agent or representative of both parties hereto. No course of
dealing or usage of trade shall be used to modify the terms and conditions herein. This Agreement
shall be binding on each of Impax and Medicis and their respective permitted successors and
assigns.

          8.3 Bankruptcy. All rights granted under this Agreement by Medicis to Impax are and
shall be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of
rights to “intellectual property” as defined under Section 101(52) of the US. Bankruptcy Code. The
parties agree that Impax, as a licensee of such rights under this Agreement, shall retain and may
fully exercise all of its rights and elections under the U.S. Bankruptcy Code, subject to
performance by Impax of its pre-existing obligations under this Agreement.

          8.4 Waiver. None of the provisions of this Agreement (including the Exhibits hereto)
shall be considered waived by any party hereto unless such waiver is agreed to, in writing, by
authorized agents of such party. The failure of a party to insist upon strict conformance to any
of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or
by law shall not be deemed a waiver of any rights of any party hereto.

          8.5 Obligations to Third Parties. Each party warrants and represents that this
Agreement does not conflict with any contractual obligations, expressed or implied, undertaken with
any Third Party.

          8.6 Assignment. Neither party shall assign this Agreement or any part hereof or any
interest herein (whether by operation of law or otherwise) to any Third Party (or use any
subcontractor) without the written approval of the other party; provided, however, that either
party may assign this Agreement without such consent (i) to any Affiliate; and (ii) in the case of
a merger, consolidation, change in control or sale of all or substantially all of the assets of the
Relevant Business Unit of the party seeking such assignment or transfer and such transaction
relates to the business or assets covered by this Agreement and the resulting entity assumes all of
the obligations under this Agreement. For the purposes of this Section 8.6, the “Relevant Business
Unit” shall mean, with respect to Impax, the generics division of Impax, and with respect to
Medicis, the medical dermatology division of Medicis. No assignment shall be valid unless the
permitted assignee(s) assumes all obligations of its assignor under this Agreement. No assignment
shall relieve any party of responsibility for the performance of its obligations hereunder. Any
purported assignment in violation of this Section 8.6 shall be void.

          8.7 Independent Contractor. Impax and Medicis are acting under this Agreement as
independent contractors and neither shall be considered an agent of, or joint venturer with, the
other. Unless otherwise provided herein to the contrary, each party shall furnish all expertise,
labor, supervision, machining and equipment necessary for the performance of its obligations
hereunder and shall obtain and maintain all building and other permits and licenses required by
public authorities.

15

 

          8.8 Governing Law. In any action brought regarding the validity, construction and
enforcement of this Agreement, it shall be governed in all respects by the laws of the State of
Arizona, without regard to the principles of conflicts of laws. The federal and state courts in
the State of Arizona shall have jurisdiction over the parties hereto in all matters arising
hereunder (except for a matter addressed in Section 2.2.3 or 3.1.2) and the parties hereto agree
that the venue with respect to such matters will be a state or federal court in the State of
Arizona.

          8.9 Severability. If any term or provision of this Agreement shall for any reason be
held invalid, illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other term or provision hereof, and this Agreement shall be
interpreted and construed as if such term or provision, to the extent the same shall have been held
to be invalid, illegal or unenforceable, had never been contained herein.

          8.10 Headings, Interpretation. The headings used in this Agreement are for
convenience only and are not part of this Agreement.

          8.11 Counterparts. The Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

[Remainder of this page intentionally blank]

16

 

IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their
duly-authorized representatives effective as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMPAX LABORATORIES, INC.	 	 	 	MEDICIS PHARMACEUTICAL CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By: 	 		 	 	 	By:	 		 	 
	 

	 	 
	 	 
	 	 	 	 	 	 
	 	 	 	 
	 

	 	Name:
	 	
	 	 	 	 	 	Name:
	 	 	 	 
	 

	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	Title:
	 	
	 	 	 	 	 	Title:
	 	 	 	 
	 

	 	 	 	 
	 	 	 	 	 	 	 	 	 	 

17

 

CONFIDENTIAL

PURSUANT TO RULE 408 PLUS AGREEMENT BETWEEN IMPAX AND MEDICIS

EXHIBIT A

Patent Rights

	 	 	 
	Issued Patents (all U.S.)	 	Pending Applications (all U.S.)
	5,908,838

	 	11/166,817
	 

	 	11/776,669
	 

	 	11/776,676
	 

	 	11/776,691
	 

	 	11/776,711
	 

	 	11/944,186
	 

	 	11/695,513
	 

	 	11/695,514
	 

	 	11/695,528
	 

	 	11/695,539
	 

	 	11/695,541
	 

	 	12/253,845

A-1

 

CONFIDENTIAL

PURSUANT TO RULE 408 PLUS AGREEMENT BETWEEN IMPAX AND MEDICIS

EXHIBIT B

Products

	 	 	 
	PRODUCT	 	NDC
	Solodyn 45mg

	 	99207-0460-30

99207-0460-10
	Solodyn 90mg

	 	99207-0461-30

99207-0461-10
	Solodyn 135mg

	 	99207-0462-30

99207-0462-10

B-1

 

CONFIDENTIAL

PURSUANT TO RULE 408 PLUS AGREEMENT BETWEEN IMPAX AND MEDICIS

EXHIBIT C

Claims

CLAIMS OF FAMILY 1

Serial No.: 11/166,817

     110. A method of treating acne vulgaris, comprising the step of:

     orally administering to a person suffering from acne vulgaris an oral minocycline
antibiotic in an amount from about 0.5 to about 1.5 mg per kilogram of body weight, wherein
said oral minocycline antibiotic is contained in a pharmaceutically suitable delivery
vehicle;

     wherein said delivery vehicle releases said oral minocycline antibiotic in such a
manner that said oral minocycline antibiotic reaches a Cmax in the person’s blood
from about 2.75 hours to about 4.0 hours after administration.

     111. The method of Claim 110, wherein said delivery vehicle releases said oral minocycline
antibiotic at a rate of:

	 	 	 	 	 
	A)

	 	about 25 to about 52 %
	 	within about 1 hour
	 

	 	about 53 to about 89 %
	 	within about 2 hours, and
	 

	 	at least about 90 %
	 	within about 4 hours; or
	B)

	 	about 30 to about 52 %
	 	within about 1 hour
	 

	 	about 53 to about 84 %
	 	within about 2 hours, and
	 

	 	at least about 85 %
	 	within about 4 hours,

wherein said release rate is measured in an aqueous physiological medium.

C-1

 

     112. The method of Claim 110, wherein the amount of said oral minocycline antibiotic is from
about 0.7 to about 1.3 mg per kilogram of body weight.

     113. The method of Claim 110, wherein said oral minocycline antibiotic is administered without
a loading dose.

     114. The method of Claim 110, wherein said oral minocycline antibiotic is minocycline as
hydrochloride.

     115. The method of Claim 114, wherein said minocycline as hydrochloride is administered once a
day.

     121. The method of Claim 110, wherein said delivery vehicle releases said oral minocycline
antibiotic in such a manner that said oral minocycline antibiotic reaches the Cmax in
the person’s blood from about 3.0 hours to about 3.75 hours after administration.

C-2

 

Serial No.: 11/776,669

     2. The oral dosage form of Claim 15, wherein said oral minocycline is minocycline as
hydrochloride.

     3. The oral dosage form of Claim 15, wherein the ratio of extragranular fast dissolving
carrier to slow dissolving carrier is 0.35 to 0.45.

     4. The oral dosage form of Claim 15, wherein the ratio of extragranular fast dissolving
carrier to slow dissolving carrier is about 0.36 to about 0.40.

     5. The oral dosage form of Claim 15, wherein said extragranular fast dissolving carrier
comprises lactose monohydrate.

     6. The oral dosage form of Claim 15, wherein said slow dissolving carrier is selected from the
group consisting of polyvinyl pyrrolidone, polyvinyl acetate, microcrystalline cellulose, methyl
cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, magnesium
stearate, and calcium stearate.

     7. The oral dosage form of Claim 15, wherein said slow dissolving carrier comprises
hydroxypropylmethyl cellulose.

C-3

 

     9. The oral dosage form of Claim 15, wherein said slow dissolving carrier is
present at:

     23.5% by weight of the oral dosage form when the oral dosage form comprises 135
mg of said oral minocycline; or

     27.0% by weight of the oral dosage form when the oral dosage
form comprises 45 mg of said oral minocycline.

     10. The oral dosage form of Claim 15, wherein the oral dosage form is formulated to release
said oral minocycline at a rate so that Cmax is reached at about 3.0 to about 3.75 hours
after administration.

     11. The oral dosage form of Claim 15, wherein the oral dosage form is a tablet or caplet
comprising 45 mg or 135 mg of said oral minocycline.

          14. The oral dosage form of Claim 15, further comprising a coating.

     15. An oral dosage form comprising:

     an antibiotically effective dose of an oral minocycline; and

     a pharmaceutically suitable delivery vehicle having an intragranular fast dissolving
carrier, an extragranular fast dissolving carrier, and a slow dissolving carrier, wherein
said minocycline, said intragranular fast dissolving carrier and said slow dissolving
carrier form granules of slow dissolving materials, and said intragranular fast dissolving
carrier is completely or partially encapsulated or included or coated in said slow
dissolving materials, wherein said extragranular fast dissolving carrier and said slow
dissolving carrier are at a weight ratio of 0.3 to 0.5;

     wherein the oral dosage form for administration once a day provides a patient with 0.7
mg/kg/day to 1.3 mg/kg/day of said oral minocycline;

C-4

 

     wherein said vehicle continuously releases, without an initial load dose, said oral
minocycline at a rate of either:

about 25 to about 52 % within about 1 hour, about 53 to about 89 % within
about 2 hours, and at least about 90 % within about 4 hours, or

about 30 to about 52 % within about 1 hour, about 53 to about 84 % within
about 2 hours, and at least about 85 % within about 4 hours.

     16. The oral dosage form of Claim 15, wherein the 0.7 mg/kg/day to 1.3 mg/kg/day of said oral
minocycline provided to the patient is about 1 mg/kg/day.

     17. An oral dosage form comprising:

     an antibiotically effective dose of an oral minocycline; and

     a pharmaceutically suitable delivery vehicle having an intragranular lactose, an
extragranular lactose, and a slow dissolving carrier, wherein said minocycline, said
intragranular lactose and said slow dissolving carrier form granules of slow dissolving
materials, and said intragranular lactose is completely or partially encapsulated or
included or coated in said slow dissolving materials, wherein said extragranular lactose and
said slow dissolving carrier are at a weight ratio of 0.3 to 0.5;

     wherein the oral dosage form for administration once a day provides a patient with 0.7
mg/kg/day to 1.3 mg/kg/day of said oral minocycline;

     wherein said vehicle continuously releases, without an initial load dose, said oral
minocycline at a rate of either about 25 to about 52 % within about 1 hour, about 53 to
about 89 % within about 2 hours, and at least about 90 % within about 4 hours, or about 30
to about 52 % within about 1 hour, about 53 to about 84 % within about 2 hours, and at least
about 85 % within about 4 hours.

C-5

 

Serial No.: 11/776,676

     1. A method of treating acne vulgaris, comprising administering to a person suffering from
acne vulgaris a continuous slow release oral dosage form comprising:

     an antibiotically effective amount of an oral minocycline antibiotic;

     a fast dissolving carrier;

     an intragranular fast dissolving carrier; and

     a slow dissolving carrier, wherein said fast dissolving carrier to said slow
dissolving carrier is at a weight ratio of about 0.3 to about 0.5;

     wherein said continuous slow release oral dosage form provides, upon administration
once daily without a loading dose, the person with about 0.7 mg/kg/day to about 1.3
mg/kg/day of said oral minocycline antibiotic.

     3. The method of Claim 1, wherein said continuous slow release oral dosage form provides the
person with about 1.0 mg/kg/day of said oral minocycline antibiotic.

     5. The method of Claim 1, wherein said oral minocycline antibiotic is minocycline as
hydrochloride.

     7. The method of Claim 1, wherein said continuous slow release oral dosage form releases said
oral minocycline antibiotic so that said oral minocycline antibiotic reaches a Cmax in
the person’s blood at about 3.5 hours after administration.

     9. The method of Claim 1, wherein said weight ratio of fast dissolving carrier to slow
dissolving carrier in said continuous slow release oral dosage form is from about 0.35 to about
0.45.

C-6

 

     10. The method of Claim 1, wherein said weight ratio of fast dissolving carrier to slow
dissolving carrier in said continuous slow release oral dosage form is from about 0.36 to about
0.40.

     12. The method of Claim 1, wherein said slow dissolving carrier encapsulates said
intragranular fast dissolving carrier.

     13. The method of Claim 1, wherein said continuous slow release oral dosage form comprises a
coating.

     14. The method of Claim 1, wherein said continuous slow release oral dosage form releases said
oral minocycline antibiotic at a rate of about 25 to about 52 % within about 1 hour, about 53 to
about 89 % within about 2 hours, and at least about 90 % within about 4 hours.

     15. The method of Claim 1, wherein said continuous slow release oral dosage form releases said
oral minocycline antibiotic at a rate of about 30 to about 52 % within about 1 hour, about 53 to
about 84 % within about 2 hours, and at least about 85 % within about 4 hours.

C-7

 

Serial No.: 11/776,691

     1. A method of treating acne vulgaris, comprising the step of:

     administering to a person suffering from acne vulgaris an oral tetracycline antibiotic
in an amount of from about 0.5 to about 1.5 mg per kilogram of body weight, wherein the oral
tetracycline antibiotic is contained in a pharmaceutically suitable delivery vehicle.

     2. The method of Claim 1, wherein the amount of oral tetracycline antibiotic is from about 0.7
to about 1.3 mg per kilogram of body weight.

     3. The method of Claim 1 or 2, wherein the oral tetracycline antibiotic is administered
without a loading dose.

     4. The method of Claim 1 or 2, wherein the oral tetracycline antibiotic is minocycline.

     5. The method of Claim 3, wherein the oral tetracycline antibiotic is minocycline.

     6. The method of Claim 4, wherein the oral tetracycline antibiotic is administered once a day.

     7. The method of Claim 5, wherein the oral tetracycline antibiotic is administered once a day.

C-8

 

     8. The method of Claim 4, wherein the delivery vehicle releases the oral
tetracycline antibiotic at a rate of:

     about 30 to about 52% within about 1 hour

     about 53 to about 84% within about 2 hours, and

     at least about 85% within about 4 hours.

     9. The method of Claim 5, wherein the delivery vehicle releases the oral tetracycline
antibiotic at a rate of:

     about 30 to about 52% within about 1 hour

     about 53 to about 84% within about 2 hours, and

     at least about 85% within about 4 hours.

     10. The method of Claim 5, wherein the delivery vehicle releases the oral tetracycline
antibiotic at a rate of:

     about 25 to about 52% within about 1 hour

     about 53 to about 89% within about 2 hours, and

     at least about 90% within about 4 hours.

     11. The method of Claim 4, wherein the delivery vehicle releases the oral tetracycline
antibiotic at a rate of:

     about 25 to about 52% within about 1 hour

     about 53 to about 89% within about 2 hours, and

     at least about 90% within about 4 hours.

     12. The method of Claim 5, wherein the delivery vehicle releases the oral tetracycline
antibiotic in such a manner that the antibiotic reaches a Cmax in the person’s blood
from about 2.75 to about 4.0 hours after administration.

C-9

 

     13. The method of Claim 12 wherein the Cmax is reached from about 3.0 to about 3.75
hours after administration.

     14. The method of Claim 4, wherein the delivery vehicle releases the oral tetracycline
antibiotic in such a manner that the antibiotic reaches a Cmax in the person’s blood
from about 2.75 to about 4.0 hours after administration.

     15. The method of Claim 14 wherein the Cmax is reached from about 3.0 to about 3.75
hours after administration.

     16. The method of Claim 5, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.3 to about 0.5.

     17. The method of Claim 5, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.35 to about 0.45.

     18. The method of Claim 5, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.36 to about 0.40.

     19. The method of Claim 4, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.3 to about 0.5.

     20. The method of Claim 4, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.35 to about 0.45.

     21. The method of Claim 4, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.36 to about 0.40.

     22. The method of Claim 6, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.3 to about 0.5.

C-10

 

     23. The method of Claim 6, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.35 to about 0.45.

     24. The method of Claim 6, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.36 to about 0.40.

     25. The method of Claim 7, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.3 to about 0.5.

     26. The method of Claim 7, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.35 to about 0.45.

     27. The method of Claim 7, wherein a ratio of fast dissolving carriers to slow dissolving
carriers in the delivery vehicle is from about 0.36 to about 0.40.

     28. An oral dosage form comprising:

     an oral tetracycline antibiotic;

     a fast dissolving carrier; and

     a slow dissolving carrier;

     wherein the fast dissolving carrier and the slow dissolving carrier are at a weight
ratio of 0.3 to 0.5 of fast dissolving carrier to slow dissolving carrier.

     29. The oral dosage form of Claim 28, wherein the ratio of fast dissolving carrier to slow
dissolving carrier is 0.35 to 0.45.

     30. The oral dosage form of Claim 28, wherein the ratio of fast dissolving carrier to slow
dissolving carrier is 0.36 to 0.40.

C-11

 

     31. The oral dosage form of Claim 28, wherein the oral tetracycline antibiotic is minocycline
as hydrochloride.

     32. The oral dosage form of Claim 29, wherein the oral tetracycline antibiotic is minocycline
as hydrochloride.

     33. The oral dosage form of Claim 30, wherein the oral tetracycline antibiotic is minocycline
as hydrochloride.

     34. The oral dosage form of Claim 28, wherein the fast dissolving carrier comprises lactose
monohydrate.

     35. The oral dosage form of Claim 29, wherein the fast dissolving carrier comprises lactose
monohydrate.

     36. The oral dosage form of Claim 30, wherein the fast dissolving carrier comprises lactose
monohydrate.

     37. The oral dosage form of Claim 28, wherein the slow dissolving carrier comprises HPMC.

     38. The oral dosage form of Claim 29, wherein the slow dissolving carrier comprises HPMC.

     39. The oral dosage form of Claim 30, wherein the slow dissolving carrier comprises HPMC.

     40. The oral dosage form of Claim 28, wherein:

     the fast dissolving carrier comprises lactose monohydrate; and

     the slow dissolving carrier comprises HPMC.

C-12

 

     41. The oral dosage form of Claim 29, wherein:

     the fast dissolving carrier comprises lactose monohydrate; and

     the slow dissolving carrier comprises HPMC.

     42. The oral dosage form of Claim 30, wherein:

     the fast dissolving carrier comprises lactose monohydrate; and

     the slow dissolving carrier comprises HPMC.

     43. The oral dosage form of Claim 40, wherein the oral tetracycline antibiotic
is minocycline as hydrochloride.

     44. The oral dosage form of Claim 41, wherein the oral tetracycline antibiotic is minocycline
as hydrochloride.

     45. The oral dosage form of Claim 42, wherein the oral tetracycline antibiotic is minocycline
as hydrochloride.

     46. The oral dosage form of Claim 28, wherein the slow dissolving carrier is present at about
23.5% to about 27.0% by weight of the oral dosage form.

     47. The oral dosage form of Claim 29, wherein the slow dissolving carrier is present at about
23.5% to about 27.0% by weight of the oral dosage form.

     48. The oral dosage form of Claim 30, wherein the slow dissolving carrier is present at about
23.5% to about 27.0% by weight of the oral dosage form.

     49. The oral dosage form of Claim 28, wherein the slow dissolving carrier
is present at:

C-13

 

     23.5% by weight of the oral dosage form when the oral dosage form comprises 135 mg of
the oral tetracycline antibiotic; or

     27.0% by weight of the oral dosage form when the oral dosage form comprises 45 mg of
the oral tetracycline antibiotic.

     50. The oral dosage form of Claim 29, wherein the slow dissolving carrier is present at:

     23.5% by weight of the oral dosage form when the oral dosage form comprises 135 mg of
the oral tetracycline antibiotic; or

     27.0% by weight of the oral dosage form when the oral dosage form comprises 45 mg of
the oral tetracycline antibiotic.

     51. The oral dosage form of Claim 30, wherein the slow dissolving carrier is present at:

     23.5% by weight of the oral dosage form when the oral dosage form comprises 135 mg of
the oral tetracycline antibiotic; or

     27.0% by weight of the oral dosage form when the oral dosage form comprises 45 mg of
the oral tetracycline antibiotic.

     52. The oral dosage form of Claim 28, which is formulated to release the oral
tetracycline antibiotic at a rate of:

     30 to 52% within 1 hour;

     53 to 84% within 2 hours; and

     at least 85% in 4 hours.

C-14

 

     53. The oral dosage form of Claim 29, which is formulated to release the oral tetracycline
antibiotic at a rate of:

     30 to 52% within 1 hour;

     53 to 84% within 2 hours; and

     at least 85% within 4 hours.

     54. The oral dosage form of Claim 30, which is formulated to release the oral tetracycline
antibiotic at a rate of:

     30 to 52% within 1 hour;

     53 to 84% within 2 hours; and

     at least 85% within 4 hours.

     55. The oral dosage form of Claim 28, wherein the oral dosage form is formulated to release
the oral tetracycline antibiotic at a rate of:

     25 to 52% within 1 hour;

     53 to 89% within 2 hours; and

     at least 90% within 4 hours.

     56. The oral dosage form of Claim 29, wherein the oral dosage form is
formulated to release the oral tetracycline antibiotic at a rate of:

     25 to 52% within 1 hour;

     53 to 89% within 2 hours; and

     at least 90% within 4 hours.

     57. The oral dosage form of Claim 30, wherein the oral dosage form is formulated to release
the oral tetracycline antibiotic at a rate of:

C-15

 

     25 to 52% within 1 hour;

     53 to 89% within 2 hours; and

     at least 90% within 4 hours.

     58. The oral dosage form of Claim 28, wherein the oral dosage form is formulated to release
the oral tetracycline antibiotic in such a manner that Cmax is reached at about 3.0 to
about 3.75 hours after administration.

     59. The oral dosage form of Claim 29, wherein the oral dosage form is formulated to release
the oral tetracycline antibiotic in such a manner that Cmax is reached at about 3.0 to
about 3.75 hours after administration.

     60. The oral dosage form of Claim 30, wherein the oral dosage form is formulated to release
the oral tetracycline antibiotic in such a manner that Cmax is reached at about 3.0 to
about 3.75 hours after administration.

     61. The oral dosage form of Claim 28, wherein the oral dosage form is a tablet or caplet
comprising 40 mg or 135 mg of the oral tetracycline antibiotic.

     62. The oral dosage form of Claim 61, wherein the oral tetracycline antibiotic is minocycline
as hydrochloride.

     63. The oral dosage form of Claim 62, wherein:

     the fast dissolving carrier comprises lactose monohydrate; and

     the slow dissolving carrier comprises HPMC.

     64. An oral dosage form comprising:

     135 mg of an oral tetracycline antibiotic; and

     23.5% by weight HPMC;

C-16

 

     wherein the oral dosage form is formulated to release the oral tetracycline antibiotic
at a rate of:

          25 to 52% within 1 hour;

          53 to 89% within 2 hours; and

          at least about 90% of the oral tetracycline antibiotic within 4 hours.

     65. The oral dosage form of Claim 64, wherein the oral tetracycline antibiotic is minocycline
as hydrochloride.

     66. The oral dosage form of Claim 64, which is a tablet or caplet.

     67. A method of treating acne vulgaris comprising:

     administering to the patient with acne vulgaris an effective amount of an oral dosage
form selected from:

	 	(A)	 	an oral dosage form comprising:

	 
	 	 	 	an oral tetracycline antibiotic;

	 
	 	 	 	a fast dissolving carrier; and

	 
	 	 	 	a slow dissolving carrier;

     wherein the fast dissolving carrier and the slow dissolving carrier are at a weight
ratio of 0.3 to 0.5; and

	 	(B)	 	an oral dosage form comprising:

	 
	 		 	135mg of an oral tetracycline antibiotic; and

	 
	 	 	 	23.5% by weight HPMC;

     wherein the oral dosage form is formulated to release the oral tetracycline antibiotic
at a rate of:

C-17

 

	 		 	25 to 52% within 1 hour;

	 
	 		 	53 to 89% within 2 hours; and

	 
	 	 	 	at least about 90% within 4 hours.

     68. The method of Claim 67, further comprising determining the weight of the patient to
calculate the effective amount of the oral dosage form.

     69. The method of Claim 68, wherein the oral dosage form is formulated to provide the patient
with about 0.5 to about 1.5 mg/kg/day of the oral tetracycline antibiotic.

     70. The method of Claim 68, wherein the oral dosage form is formulated to provide the patient
with about 0.7 to about 1.3 mg/kg/day of the oral tetracycline antibiotic.

     71. The method of Claim 68, wherein the oral dosage form is formulated to provide the patient
with about 1.0 mg/kg/day of the oral tetracycline antibiotic.

     72. The method of Claim 67, wherein the oral tetracycline antibiotic is minocycline as
hydrochloride.

     73. The method of Claim 67, wherein the oral dosage form is administered once a day.

     74. The method of Claim 67, wherein the oral dosage form is administered without a loading
dose.

     75. The method of Claim 67, wherein the oral dosage form is (A).

     76. The method of Claim 67, wherein the oral dosage form is (B).

C-18

 

     77. The method of Claim 67, wherein the oral tetracycline antibiotic reaches Cmax
at about 3.0 to about 3.75 hours after administration.

     78. A method of preparing an oral dosage form, comprising combining an oral tetracycline
antibiotic with a fast dissolving carrier and a slow dissolving carrier to form a combination,
wherein the fast dissolving carrier and the slow dissolving carrier are at a weight ratio of 0.3 to
0.5 of fast dissolving carrier to slow dissolving carrier.

     79. The method of Claim 78, wherein the weight ratio of fast dissolving carrier to slow
dissolving carrier is 0.35 to 0.45.

     80. The method of Claim 78, wherein the weight ratio of fast dissolving carrier to slow
dissolving carrier is 0.36 to 0.40.

     81. The method of Claim 78, wherein the oral tetracycline antibiotic is minocycline as
hydrochloride.

     82. The method of Claim 79, wherein the oral tetracycline antibiotic is minocycline as
hydrochloride.

     83. The method of Claim 80, wherein the oral tetracycline antibiotic is minocycline as
hydrochloride.

     84. The method of Claim 78, wherein the fast dissolving carrier comprises lactose monohydrate.

     85. The method of Claim 79, wherein the fast dissolving carrier comprises lactose monohydrate.

     86. The method of Claim 80, wherein the fast dissolving carrier comprises lactose monohydrate.

C-19

 

     87. The method of Claim 78, wherein the slow dissolving carrier comprises HPMC.

     88. The method of Claim 79, wherein the slow dissolving carrier comprises HPMC.

     89. The method of Claim 80, wherein the slow dissolving carrier comprises HPMC.

     90. The method of Claim 78, wherein:

     the fast dissolving carrier comprises lactose monohydrate; and

     the slow dissolving carrier comprises HPMC.

     91. The method of Claim 79, wherein:

     the fast dissolving carrier comprises lactose monohydrate; and

     the slow dissolving carrier comprises HPMC.

     92. The method of Claim 80, wherein:

     the fast dissolving carrier comprises lactose monohydrate; and

     the slow dissolving carrier comprises HPMC.

     93. The method of Claim 90, wherein the oral tetracycline antibiotic is minocycline as
hydrochloride.

     94. The method of Claim 91, wherein the oral tetracycline antibiotic is minocycline as
hydrochloride.

     95. The method of Claim 92, wherein the oral tetracycline antibiotic is minocycline as
hydrochloride.

C-20

 

     96. The method of Claim 78, wherein the slow dissolving carrier is present at about 23.5 to
about 27.0% by weight of the oral dosage form.

     97. The method of Claim 79, wherein the slow dissolving carrier is present at about 23.5% to
about 27.0% by weight of the oral dosage form.

     98. The method of Claim 80, wherein the slow dissolving carrier is present at
about 23.5% to about 27.0% by weight of the oral dosage form.

     99. The method of Claim 78, wherein the slow dissolving carrier is present at:

     23.5% by weight of the oral dosage form when the oral dosage form comprises 135 mg of
the oral tetracycline antibiotic; or

     27.0% by weight of the oral dosage form when the oral dosage form comprises 45 mg of
the oral tetracycline antibiotic.

     100. The method of Claim 79, wherein the slow dissolving carrier is present at:

     23.5% by weight of the oral dosage form when the oral dosage form comprises 135 mg of
the oral tetracycline antibiotic; or

     27.0% by weight of the oral dosage form when the oral dosage form comprises 45 mg of
the oral tetracycline antibiotic.

     101. The method of Claim 80, wherein the slow dissolving carrier is present at:

     23.5% by weight of the oral dosage form when the oral dosage form comprises 135 mg of
the oral tetracycline antibiotic; or

C-21

 

     27.0% by weight of the oral dosage form when the oral dosage form comprises 45 mg of
the oral tetracycline antibiotic.

     102. The method of Claim 78, further comprising compressing the combination into a tablet.

     103. The method of Claim 102, further coating the tablet with Opadry II.

     104. A method of preparing an oral dosage form comprising combining an oral tetracycline
antibiotic with 23.5% by weight of HPMC to form a combination, wherein the oral dosage form
comprises 135 mg of an oral tetracycline antibiotic and the oral dosage form is formulated to
release the oral tetracycline antibiotic at a rate of:

          25 to 52% within 1 hour;

          53 to 89% within 2 hours; and

          at least about 90% within 4 hours.

     105. The method of Claim 104, wherein the oral tetracycline antibiotic is minocycline as
hydrochloride.

     106. The method of Claim 104, further comprising compressing the combination into a tablet.

     107. The method of Claim 106 further coating the tablet with Opadry II.

C-22

 

Serial No.: 11/776,711

     1. A method of preparing an oral dosage form for administration once a day that provides a
slow, continuous release, without an initial load dose, of an oral minocycline, comprising:

     combining an antibiotically effective dose of said oral minocycline and a
pharmaceutically suitable delivery vehicle having an intragranular fast dissolving carrier,
an extragranular fast dissolving carrier, and a slow dissolving carrier, wherein said
minocycline, said intragranular fast dissolving carrier and said slow dissolving carrier
form granules of slow dissolving materials, and said intragranular fast dissolving carrier
is completely or partially encapsulated or included or coated in said slow dissolving
materials, wherein said extragranular fast dissolving carrier and said slow dissolving
carrier are at a weight ratio of 0.3 to 0.5 of extragranular fast dissolving carrier to slow
dissolving carrier;

     wherein said oral dosage form upon administration releases said oral minocycline to
provide a patient with 0.7 mg/kg/day to 1.3 mg/kg/day of said oral minocycline.

     2. The method of Claim 1, wherein said oral minocycline is minocycline as hydrochloride.

     3. The method of Claim 1, wherein the weight ratio of extragranular fast dissolving carrier to
slow dissolving carrier is 0.35 to 0.45.

     4. The method of Claim 1, wherein the weight ratio of extragranular fast dissolving carrier to
slow dissolving carrier is about 0.36 to about 0.40.

C-23

 

     5. The method of Claim 1, wherein said extragranular fast dissolving carrier comprises lactose
monohydrate.

     6. The method of Claim 1, wherein said slow dissolving carrier comprises HPMC.

     7. The method of Claim 1, wherein:

     said extragranular fast dissolving carrier comprises lactose monohydrate; and

     said slow dissolving carrier comprises HPMC.

     9. The method of Claim 1, wherein said slow dissolving carrier is present at:

     23.5% by weight of said oral dosage form when said oral dosage form comprises 135 mg of
said oral minocycline; or

     27.0% by weight of said oral dosage form when said oral dosage form comprises 45 mg of
said oral minocycline.

     10. The method of Claim 1, wherein compressing said combination forms said oral dosage form
into a tablet.

     14. The method of Claim 1, further comprising adding a coating to said combination to form
said oral dosage form.

     15. The method of Claim 1, further comprising compressing said combination.

C-24

 

     16. The method of Claim 1, wherein the intragranular fast dissolving carrier is lactose, and
wherein the extragranular fast dissolving carrier is lactose.

C-25

 

Serial No.: 11/944,186

     6. An oral dosage form, comprising:

     an antibiotically effective dose of an oral minocycline; and

     a pharmaceutically suitable delivery vehicle;

     wherein said oral dosage form is for administration once daily to provide a patient
with about 0.5 mg/kg/day to about 1.5 mg/kg/day of said oral minocycline; and

     wherein said oral dosage form provides a continuous slow release, without a loading
dose, of said oral minocycline, at a release rate in gastric fluid of either about 25 % to
about 52 % within about 1 hour, about 53 % to about 89 % within about 2 hours, and at least
about 90 % within about 4 hours, or about 30 % to about 52 % within about 1 hour, about 53 %
to about 84 % within about 2 hours, and at least about 85 % within about 4 hours.

     7. The oral dosage form of Claim 6, wherein said oral minocycline is minocycline as
hydrochloride.

     8. The oral dosage form of Claim 6, wherein said oral dosage form is for administration once
daily to provide said patient with about 1.0 mg/kg/day of said oral minocycline.

C-26

 

     9. An oral dosage form, comprising:

     an antibiotically effective dose of an oral minocycline; and

     a pharmaceutically suitable delivery vehicle;

     wherein said oral dosage form is for administration once daily to provide a patient
with about 0.5 mg/kg/day to about 1.5 mg/kg/day of said oral minocycline; and

     wherein said oral dosage form does not provide an immediate release of said oral
minocycline, and provides a continuous slow release, without a loading dose, of said oral
minocycline at a rate so that Cmax is reached at about 3.5 hours after
administration to said patient.

     10. The oral dosage form of Claim 9, wherein said oral minocycline is minocycline as
hydrochloride.

     11. The oral dosage form of Claim 9, wherein said oral dosage form is for administration once
daily to provide said patient with about 1.0 mg/kg/day of said oral minocycline.

     12. An oral dosage form, comprising:

     an antibiotically effective dose of an oral minocycline;

     a fast dissolving carrier; and

     a slow dissolving carrier, wherein said fast dissolving carrier and said slow
dissolving carrier are at a weight ratio of about 0.3 to      about 0.5 that provides a
continuous, slow release, without immediate release, of said oral minocycline; and

C-27

 

     wherein said oral dosage form is for administration once daily to provide a patient
with about 0.5 mg/kg/day to about 1.5 mg/kg/day of said oral minocycline.

     13. The oral dosage form of Claim 12, wherein said oral minocycline is minocycline as
hydrochloride.

     14. The oral dosage form of Claim 12, wherein said weight ratio of fast dissolving carrier to
slow dissolving carrier is 0.35 to 0.45.

     15. The oral dosage form of Claim 14, wherein said weight ratio of fast dissolving carrier to
slow dissolving carrier is 0.36 to 0.40.

     16. The oral dosage form of Claim 12, wherein said oral dosage form is for administration once
daily to provide said patient with about 1.0 mg/kg/day of said oral minocycline.

     17. The oral dosage form of Claim 12, further comprising an intragranular fast dissolving
carrier.

     18. The oral dosage form of Claim 17, wherein said slow dissolving carrier encapsulates said
intragranular fast dissolving carrier.

     19. The oral dosage form of Claim 18, further comprising a coating

C-28

 

CLAIMS OF FAMILY 2

Serial No.: 11/695,513

     1. A method of administering an oral dosage form comprising:

     (i) administering to a patient an oral dosage form, which oral
dosage form

     comprises:

          an oral tetracycline-class antibiotic;

          a fast dissolving carrier; and

          a slow dissolving carrier; and

     (ii) providing information to the patient, wherein the information comprises that the
administering of the oral dosage form may cause one or more adverse effects selected from
pseudomembranous colitis, hepatotoxicity, vasculitis, tissue hyperpigmentation, and
anaphylaxis.

     2. The method of Claim 1, wherein the fast dissolving carrier and the slow dissolving carrier
are at a weight ratio of from 0.3 to 0.5 of fast dissolving carrier to slow dissolving carrier.

     3. The method of Claim 1, wherein the fast dissolving carrier and the slow dissolving carrier
are at a weight ratio of from 0.3 to 0.45 of fast dissolving carrier to slow dissolving carrier.

     4. The method of Claim 1, wherein the fast dissolving carrier and the slow dissolving carrier
are at a weight ratio of from about 0.36 to 0.40 of fast dissolving carrier to slow dissolving
carrier.

     5. The method of Claim 1, wherein the adverse effect is pseudomembranous colitis.

     6. The method of Claim 1, wherein the adverse effect is hepatotoxicity.

C-29

 

     7. The method of Claim 1, wherein the adverse effect is vasculitis.

     8. The method of Claim 1, wherein the adverse effect is tissue hyperpigmentation.

     9. The method of Claim 1, wherein the adverse effect is anaphylaxis.

     10. The method of Claim 1, wherein the patient has been diagnosed with acne vulgaris.

     11. A method of distributing an oral dosage form, comprising:

     distributing an oral dosage form comprising an oral tetracycline-class antibiotic, a
fast dissolving carrier and a slow dissolving carrier; and

     concomitantly distributing information that the oral dosage form may cause one or more
adverse effects selected from pseudomembranous colitis, hepatotoxicity, vasculitis, tissue
hyperpigmentation, and anaphylaxis.

     12. The method of Claim 11, wherein the fast dissolving carrier and the slow dissolving
carrier are at a weight ratio of from 0.3 to 0.5 of fast dissolving carrier to slow dissolving
carrier.

     13. The method of Claim 11, wherein the fast dissolving carrier and the slow dissolving
carrier are at a weight ratio of from 0.35 to 0.45 of fast dissolving carrier to slow dissolving
carrier.

     14. The method of Claim 11, wherein the fast dissolving carrier and the slow dissolving
carrier are at a weight ratio of from about 0.36 to 0.40 of fast dissolving carrier to slow
dissolving carrier.

C-30

 

     15. The method of Claim 11, wherein the adverse effect is pseudomembranous colitis.

     16. The method of Claim 11, wherein the adverse effect is hepatotoxicity.

     17. The method of Claim 11, wherein the adverse effect is vasculitis.

     18. The method of Claim 11, wherein the adverse effect is tissue hyperpigmentation.

     19. The method of Claim 11, wherein the adverse effect is anaphylaxis.

C-31

 

Serial No.: 11/695,514

     2. The oral dosage form of Claim 3, wherein said oral dosage form administered once-daily
provides1 substantially similar or better acne treatment efficacy and reduced
incidence of at least one adverse effect, as compared to a twice-daily administration of said
MINOCIN® immediate-release minocycline hydrochloride.

     3. An oral dosage form, comprising:

     minocycline or a pharmaceutically acceptable salt thereof; and

     an amount of a controlled-release carrier composition that is effective to render said
oral dosage form pharmacokinetically distinct from MINOCIN® immediate-release minocycline
hydrochloride, wherein said oral dosage form provides, after administration, at least one in
vivo plasma minocycline concentration profile selected from:

	 	(a)	 	a single-dosage Cmax that is about 80%
or less of the single-dosage Cmax of the MINOCIN®
immediate-release minocycline hydrochloride;
	 
	 	(b)	 	a steady-state Cmax that is about 80%
or less of the steady-state Cmax of the MINOCIN®
immediate-release minocycline hydrochloride;
	 
	 	(c)	 	a single-dosage AUC(0-72) that is
about 80% or less of the single-dosage AUC(0-72) of the
MINOCIN® immediate-release minocycline hydrochloride;
	 
	 	(d)	 	a steady state AUC(0-72) that is about
80% or less of the steady state AUC(0-72) of the MINOCIN®
immediate-release minocycline

 

			
	1	 	The word “provides” was erroneously stricken in a
response to restriction requirement having a mail room date of October 27,
2008. Future prosecution will correct such erroneous striking.

C-32

 

	 	 	 	hydrochloride;
	 
	 	(e)	 	a single-dosage Tmax that is at least
about 125% of the single-dosage Tmax of the MINOCIN®
immediate-release minocycline hydrochloride; and
	 
	 	(f)	 	a steady state Tmax that is at least
about 125% of the steady state Tmax of the MINOCIN®
immediate-release minocycline hydrochloride.

     4. The oral dosage form of Claim 3, wherein said in vivo plasma
minocycline concentration profile is dose-adjusted to a 100 mg dosage and wherein:

     said single-dosage Cmax is in the range of about 0.9 μg/mL to about 1.5
μg/mL;

     said single-dosage AUC(0-72) is in the range of about 25 μg x hr/mL to about
30 μg x hr/mL; or

     said single-dosage Cmax in the range of about 0.9 μg/mL to about 1.5 μg/mL
and said single-dosage AUC(0-72) is in the range of about 25 μg x hr/mL to about
30 μg x hr/mL.

     5. The oral dosage form of Claim 3, wherein said single-dosage Tmax in the range of
about 3.2 to about 4.5 hours.

     6. The oral dosage form of Claim 5, wherein said single-dosage Tmax is in the range
of about 3.5 to about 4.0 hours.

     7. The oral dosage form of Claim 4, wherein said single-dosage Cmax is in the range
of about 1.1 μg/mL to about 1.4 μg/mL.

C-33

 

     8. The oral dosage form of Claim 4, wherein said single-dosage AUC(0-72) is in the
range of about 27 μg x hr/mL to about 29 μg x hr/mL.

     9. The oral dosage form of Claim 3, wherein said in vivo plasma minocycline concentration
profile is dose-adjusted to a 100 mg dosage and wherein:

     said steady-state Cmax is in the range of about 2.0 μg/mL to about 2.8
μg/mL;

     said steady-state AUC(0-24) is in the range of about 25 μg x hr/mL to about
40 μg x hr/mL; or

     said steady-state Cmax is in the range of about 2.0 μg/mL to about 2.8 μg/mL
and said steady-state AUC(0-24) is in the range of about 25 μg x hr/mL to about
40 μg x hr/mL.

     10. The oral dosage form of Claim 3, wherein said steady-state Tmax in the range of
about 3.2 to about 4.5 hours.

     11. The oral dosage form of Claim 10, wherein said steady-state Tmax is in the
range of about 3.5 to about 4.0 hours.

     12. The oral dosage form of Claim 9, wherein said steady-state Cmax is in the range
of about 2.2 μg/mL to about 2.6 μg/mL.

     13. The oral dosage form of Claim 9, wherein said steady-state AUC(0-72) is in the
range of about 28 μg x hr/mL to about 37 μg x hr/mL.

     14. The oral dosage form of Claim 1, wherein said minocycline salt is minocycline
hydrochloride.

C-34

 

     15. The oral dosage form of Claim 3 or Claim 14, wherein said oral dosage form is in a unit
dosage form suitable for administration to a human at a minocycline free base equivalent dosage in
the range of about 0.75 mg/kg to about 1.5 mg/kg.

     16. The oral dosage form of Claim 15, wherein said unit dosage form comprises minocycline
hydrochloride in a minocycline free base equivalent amount selected from about 45 mg, about 60 mg,
about 90 mg and about 135 mg.

     17. The oral dosage form of Claim 3, wherein said in vivo plasma minocycline concentration
profile is single-dosage Cmax.

     18. The oral dosage form of Claim 3, wherein said in vivo plasma minocycline concentration
profile is single-dosage AUC(0-72).

     19. The oral dosage form of Claim 3, wherein said in vivo plasma minocycline concentration
profile is single-dosage Tmax.

     20. The oral dosage form of Claim 3, wherein said in vivo plasma minocycline concentration
profile is steady-state Cmax.

     21. The oral dosage form of Claim 3, wherein said in vivo plasma minocycline concentration
profile is steady-state AUC(0-72).

     22. The oral dosage form of Claim 3, wherein said in vivo plasma minocycline concentration
profile is steady-state Tmax

     23. The oral dosage form of Claim 3, wherein said oral dosage form provides, after
administration, at least two of said in vivo plasma minocycline concentration profiles.

     24. The oral dosage form of Claim 3, wherein said oral dosage form provides said single-dosage
Cmax, said single-dosage AUC(0-72) and said single-dosage Tmax.

C-35

 

     25. The oral dosage form of Claim 3, wherein said oral dosage form provides said steady-state
Cmax, said steady-state AUC(0-72) and said steady-state Tmax.

     26. The oral dosage form of Claim 1, wherein said controlled-release carrier composition
comprises at least one selected from hydroxypropylmethylcellulose, hydroxypropylcellulose, and
polyvinylpryrollidone.

     27. A method of distributing minocycline, comprising:

     distributing the oral dosage form of Claim 3 or Claim 14; and

     concomitantly distributing information that the oral dosage form may cause an adverse
effect.

     28. The method of Claim 27, wherein the adverse effect is selected from ear and labyrinth
disorders, eye disorders, gastrointestinal disorders, immune system disorders, infections and
infestations, laboratory blood abnormalities, metabolism and nutritional disorders, musculoskeletal
and connective disorders, nervous system disorders, psychiatric disorders, renal and urinary
disorders, reproductive system and breast disorders, respiratory, thoracic and mediastinal
disorders, skin and subcutaneous tissue disorders, vascular disorders, pseudomembranous colitis,
hepatotoxicity, vasculitis, tissue hyperpigmentation, and anaphylaxis.

     29. The method of Claim 27, wherein the adverse effect is selected from gastrointestinal
disorders, blurred vision, autoimmune syndromes, and adverse renal reactions.

     30. A method of making the oral dosage form of Claim 3, comprising intermixing the minocycline
or pharmaceutically acceptable salt thereof and the controlled-release carrier composition to form
an admixture.

C-36

 

     31. The method of Claim 30, further comprising forming the admixture into a unit dosage form.

     32. The method of Claim 31, wherein forming the admixture into the unit dosage form comprises
compressing the admixture into tablets.

     33. A kit comprising:

     the minocycline oral dosage form of Claim 3; and

     information that the oral dosage form may cause one or more adverse effects.

     34. The kit of Claim 33, wherein the adverse effect is selected from ear and labyrinth
disorders, eye disorders, gastrointestinal disorders, immune system disorders, infections and
infestations, laboratory blood abnormalities, metabolism and nutritional disorders, musculoskeletal
and connective disorders, nervous system disorders, psychiatric disorders, renal and urinary
disorders, reproductive system and breast disorders, respiratory, thoracic and mediastinal
disorders, skin and subcutaneous tissue disorders, vascular disorders, pseudomembranous colitis,
hepatotoxicity, vasculitis, tissue hyperpigmentation, and anaphylaxis.

     35. The kit of Claim 33, wherein the adverse effect is selected from gastrointestinal
disorders, blurred vision, autoimmune syndromes, and adverse renal reactions.

     36. The kit of Claim 33, further comprising instructions for administering the oral dosage
form at a minocycline free base equivalent dosage of about 0.75 mg/kg to about 1.5 mg/kg.

C-37

 

Serial No.: 11/695,528

     1. A method of administering an oral dosage form for the treatment of acne comprising:

     (i) administering to a patient the oral dosage form, the oral dosage form comprising:

	 	(a)	 	an intragranular blend of:
	 		 	90 mg of minocycline hydrochloride;
	 		 	108 mg of the matrix-forming polymer hydroxypropyl
	 	 	 	methylcellulose; and
	 		 	152mg of an intragranular lactose; and

	 	(b)	 	an extragranular excipient that completely or partially
	 	 	 	encapsulates or coats the intragranular blend, the extragranular
	 	 	 	excipients include 41 mg of extragranular lactose monohydrate; and

     wherein the dosage form provides a patient with 0.75 mg/kg to 1.5 mg/kg of the
minocycline hydrochloride in a slow, continuous fashion, without an initial load dose, that
effectively treats acne of the patient by the once daily administration of the dosage form,
and

     (ii) providing information to the patient, which information comprises results of
performed clinical trials including a comparison of the oral dosage form to placebo with
respect to an aspect of the at least one adverse effect.

     4. The method of Claim 1, wherein the at least one adverse effects is selected from the group
consisting of one or more: headache, fatigue, dizziness, pruritus, malaise, mood alteration,
somnolence, urticaria, tinnitus, vertigo, dry mouth, and myalgia.

C-38

 

     18. The method of Claim 1, wherein the oral dosage form provides the patient with about 1.0
mg/kg/day of the minocycline hydrochloride.

     19. The method of Claim 1, wherein the oral tetracycline-class antibiotic is released so that
the minocycline hydrochloride reaches Cmax in a person’s blood from about 3.2 hours to
about 4.5 hours after administration.

     20. The method of Claim 1, wherein the acne is selected from the group consisting of acne
vulgaris, acne rosacea, acne conglobata, acne fulminans, gram-negative folliculitis, and pyoderma
faciale.

     21. The method of Claim 1, wherein the information includes information about one or more
deleterious effects selected from the group consisting of: gastrointestinal disorders, blurred
vision, autoimmune syndromes, and adverse renal reactions.

     22. The method of Claim 1, wherein the matrix-forming polymer hydroxypropyl methylcellulose is
about 26% to about 28% by weight based on the total weight of the dosage form.

     23. The method of Claim 21, wherein the extragranular excipients further comprise 9 mg of
silicon oxide and magnesium stearate, and wherein the dosage form has a total core weight, without
coating, of 400mg.

C-39

 

Serial No.: 11/695,539

     8. The minocycline oral dosage form of Claim 27 , wherein the matrix-forming polymer
hydroxypropyl methylcellulose is about 26% to about 28% by weight based on the total weight of the
dosage form.

     23. A kit comprising:

     the minocycline oral dosage form of Claim 27 ; and

     information that the oral dosage form may cause one or more adverse effects.

     24. The kit of Claim 23, wherein the one or more adverse effects is selected from group
consisting of one or more of: headache, fatigue, dizziness, pruritus, malaise, mood alteration,
somnolence, urticaria, tinnitus, vertigo, dry mouth, and myalgia.

     25. The kit of Claim 24, further comprising additional information about one or more
deleterious effects selected from the group consisting of: gastrointestinal disorders, blurred
vision, autoimmune syndromes, and adverse renal reactions.

     26. The kit of Claim 23, further comprising instructions for administering the oral dosage
form.

     27. A minocycline oral dosage form for the treatment of acne, comprising:

	 	(i)	 	an intragranular blend of:
	 		 	90 mg of minocycline hydrochloride;
	 		 	108 mg of the matrix-forming polymer hydroxypropyl
	 	 	 	methylcellulose; and

C-40

 

	 	 	 	152 mg of an intragranular lactose; and

     (ii) an extragranular excipient that completely or partially encapsulates or
coats the intragranular blend, the extragranular excipient includes 41 mg of
extragranular lactose monohydrate; and

     wherein the dosage form provides a patient with about 1 mg/kg of the minocycline in a
slow, continuous fashion, without an initial load dose, that effectively treats acne of the
patient by the once daily administration of the dosage form.

     28. The dosage form of Claim 27, wherein the extragranular excipient further comprises 9 mg of
silicon oxide and magnesium stearate, and wherein the dosage form has a total core weight, without
coating, of 400mg.

     29. The minocycline oral dosage form of Claim 27, further comprising a film coat in an amount
about 2% to about 3% of the total weight of the dosage form.

C-41

 

Serial No.: 11/695,541

     1. A method of treating acne, comprising administering an oral dosage form to a subject in
need thereof, wherein said oral dosage form comprises:

     minocycline or a pharmaceutically acceptable salt thereof; and

     an amount of a controlled-release carrier composition that is effective to render said
oral dosage form pharmacokinetically distinct from MINOCIN® immediate-release minocycline
hydrochloride.

     2. The method of Claim 1, comprising administering the oral dosage form to the subject at a
minocycline free base equivalent dosage in the range of about 0.75 mg/kg to about 1.5 mg/kg.

     3. The method of Claim 1, comprising administering the oral dosage form to the subject on a
once-daily basis.

     4. The method of Claim 1, further comprising reducing at least one adverse side effect as
compared to that expected from administering the MINOCIN® immediate-release minocycline
hydrochloride.

     5. The method of Claim 4, wherein reducing at least one adverse side effect comprises reducing
the likelihood of experiencing said adverse side effect.

     6. The method of Claim 4, wherein reducing at least one adverse side effect comprises reducing
the magnitude of said adverse side effect.

     7. The method of Claim 4, wherein reducing at least one adverse side effect comprises reducing
the duration of said adverse side effect.

C-42

 

     8. The method of Claim 1, further comprising informing the subject that the oral dosage form
may cause an adverse effect.

     9. The method of Claim 8, wherein the adverse effect is selected from ear and labyrinth
disorders, eye disorders, gastrointestinal disorders, immune system disorders, infections and
infestations, laboratory blood abnormalities, metabolism and nutritional disorders, musculoskeletal
and connective disorders, nervous system disorders, psychiatric disorders, renal and urinary
disorders, reproductive system and breast disorders, respiratory, thoracic and mediastinal
disorders, skin and subcutaneous tissue disorders, vascular disorders, pseudomembranous colitis,
hepatotoxicity, vasculitis, tissue hyperpigmentation, and anaphylaxis.

     10. The method of Claim 8, wherein the adverse effect is selected from gastrointestinal
disorders, blurred vision, autoimmune syndromes, and adverse renal reactions.

     11. The oral dosage form of Claim 1, wherein said minocycline salt is minocycline
hydrochloride.

     12. The method of Claim 11, comprising administering the oral dosage form to the subject at a
minocycline free base equivalent dosage in the range of about 0.75 mg/kg to about 1.5 mg/kg.

     13. The method of Claim 11, comprising administering the oral dosage form to the subject on a
once-daily basis.

     14. The method of Claim 11, further comprising reducing at least one adverse side effect as
compared to that expected from administering the MINOCIN® immediate-release minocycline
hydrochloride.

     15. The method of Claim 14, wherein reducing at least one adverse side effect comprises
reducing the likelihood of experiencing said adverse side effect.

C-43

 

     16. The method of Claim 14, wherein reducing at least one adverse side effect comprises
reducing the magnitude of said adverse side effect.

     17. The method of Claim 14, wherein reducing at least one adverse side effect comprises
reducing the duration of said adverse side effect.

     18. The method of Claim 11, further comprising informing the subject that the oral dosage form
may cause an adverse effect.

     19. The method of Claim 18, wherein the adverse effect is selected from ear and labyrinth
disorders, eye disorders, gastrointestinal disorders, immune system disorders, infections and
infestations, laboratory blood abnormalities, metabolism and nutritional disorders, musculoskeletal
and connective disorders, nervous system disorders, psychiatric disorders, renal and urinary
disorders, reproductive system and breast disorders, respiratory, thoracic and mediastinal
disorders, skin and subcutaneous tissue disorders, vascular disorders, pseudomembranous colitis,
hepatotoxicity, vasculitis, tissue hyperpigmentation, and anaphylaxis.

     20. The method of Claim 18, wherein the adverse effect is selected from gastrointestinal
disorders, blurred vision, autoimmune syndromes, and adverse renal reactions.

C-44

 

Serial No.: 12/253,845

     1. A minocycline oral dosage form for treatment of acne, comprising minocycline or a
pharmaceutically acceptable salt thereof; and

     an amount of a controlled-release carrier, said controlled-release carrier comprising a slow
dissolving carrier, an intragranular fast dissolving carrier, and an extragranular fast dissolving
carrier, wherein said controlled-release carrier provides a release rate in gastric fluid of the
minocycline or a pharmaceutically acceptable salt thereof that is either about 25% to about 52%
within 1 hour, about 53% to about 89% within 2 hours, and at least 90% within about 4 hours, or
about 30% to about 52% within 1 hour, about 53% to about 84% within 2 hours, and at least 85%
within about 4 hours, so that there is a reduction in adverse side effects, and a patient receives,
without an initial load dose, about 0.75 mg/kg/day to about 1.5 mg/kg/day of the minocycline or the
pharmaceutically acceptable salt thereof by a once daily administration.

     2. The dosage form of Claim 1, wherein said controlled-release carrier comprises at least one
ingredient selected from hydroxypropylmethylcellulose, hydroxypropylcellulose, and
polyvinylpyrrolidone.

     3. The dosage form of Claim 1, wherein said controlled-release carrier is present in the range
of about 20% to about 30%, by weight based on the total weight of the minocycline oral dosage form.

     4. The dosage form of Claim 1, wherein the minocycline salt comprises minocycline
hydrochloride.

     5. The dosage form of Claim 1, wherein the dosage form is administered to the patient at a
minocycline free base equivalent dosage in the amount about 1 mg/kg/day.

     6. The dosage form of Claim 5, wherein the dosage form is selected from the group consisting
of 45 mg, 90 mg and 135 mg.

C-45

 

     7. The dosage form of Claim 6, wherein the dosage form is present in an amount of 45 mg, and
said controlled-release carrier is present in an amount of about 26% to about 28% by weight based
on the total weight of the minocycline oral dosage form.

     8. The dosage form of Claim 6, wherein the oral dosage form is present in an amount of 135 mg,
and said controlled-release carrier is present in an amount of about 22% to less than 25% by weight
based on the total weight of the dosage form.

     9. The dosage form of Claim 1, wherein said extragranular fast dissolving carrier is present
in an amount of 41 mg based on the total weight of the dosage form.

     10. The dosage form of Claim 1, wherein said intragranular fast dissolving carrier and said
slow dissolving carrier are each in an amount greater than said extragranular fast dissolving
carrier.

     11. The dosage form of Claim 1, further comprising a film coat in an amount about 2 to 3% of
the total weight of the dosage form.

     12. The dosage form of Claim 1, wherein said intragranular fast dissolving carrier and said
slow dissolving carrier are each in an amount greater than said extragranular fast dissolving
carrier.

C-46

 

     13. An oral dosage form for the treatment of acne, comprising:

     an amount of minocycline free base equivalent of minocycline
hydrochloride, wherein the amount is one selected from the group consisting of 45mg, 90mg
and 135mg;

     a matrix-forming polymer, wherein the matrix-forming polymer is in an
amount of 108 mg for 45mg or 90 mg dosage forms, and in an amount of 94 mg for 135 mg dosage
form;

          an intragranular lactose monohydrate; and

          an extragranular lactose monohydrate,

     wherein the dosage form provides a patient with about 0.75 mg/kg/day to about 1.5
mg/kg/day of the minocycline in a slow, continuous fashion, without an initial load dose,
that effectively treats acne of the patient and reduces adverse vestibular side effects by a
once daily administration of the dosage form.

     14. The dosage form of Claim 13, wherein the matrix-forming polymer is hydroxypropyl
methylcellulose.

     15. The dosage form of Claim 14, wherein the extragranular lactose monohydrate is present in
an amount of 41 mg.

     16. The dosage form of claim 14, further comprising 9 mg of silicon oxide and magnesium
stearate, and wherein the dosage form has a total core weight, without coating, of 400mg.

     17. The dosage form of Claim 13, wherein the about 0.75 mg/kg/day to about 1.5 mg/kg/day of
the minocycline or a pharmaceutically acceptable salt thereof is about 1 mg/kg/day.

     18. The dosage form of Claim 13, further comprising a film coat in an amount about 2 to 3% of
the total weight of the dosage form.

     19. A minocycline oral dosage form for the treatment of acne, comprising:

C-47

 

          45 mg of minocycline hydrochloride;

          108 mg of the matrix-forming polymer hydroxypropyl methylcellulose;

          197 mg of intragranular lactose;

          41 mg of extragranular lactose monohydrate; and

     wherein the dosage form provides a patient with about 1 mg/kg/day of the minocycline in
a slow, continuous fashion, without an initial load dose, that effectively treats acne of
the patient and with a reduction in normal adverse vestibular side effects by a once daily
administration of the dosage form.

     20. The dosage form Claim 19, further comprising 9 mg of silicon oxide and magnesium stearate,
wherein the dosage form has a total core weight, without coating, of 400mg.

C-48

 

     21. A minocycline oral dosage form for the treatment of acne, comprising:

          135 mg of minocycline hydrochloride;

          94 mg of the matrix-forming polymer hydroxypropyl

          methylcellulose;

          121 mg of intragranular of lactose monohydrate;

          41 mg of extragranular lactose monohydrate; and

     wherein the dosage form provides a patient with about 1 mg/kg/day of the minocycline in
a slow, continuous fashion, without an initial load dose, that effectively treats acne of
the patient and with a reduction in normal adverse vestibular side effects by a once daily
administration of the dosage form.

     22. The dosage form of Claim 21, further comprising 9 mg of silicon oxide and magnesium
stearate, wherein the dosage form has a total core weight, without coating, of 400mg.

     23. A kit comprising:

     the dosage form of claim 1; and

     information concerning the adverse side effects that may be caused by the
dosage form.

     24. The kit of Claim 23, wherein the adverse side effects is selected from group consisting of
one or more of: headache, fatigue, dizziness, pruritus, malaise, mood alteration, somnolence,
urticaria, tinnitus, vertigo, dry mouth, and myalgia.

     25. The kit of Claim 24, further comprising additional information about one or more
deleterious effects that may be caused by the dosage form, wherein the additional information is
selected from the group consisting of: gastrointestinal disorders, blurred vision, autoimmune
syndromes, and adverse renal reactions.

     26. The kit of Claim 25, further comprising instructions for administering the oral dosage
form.

     27. A method of administering an oral dosage form for the treatment of acne comprising:

C-49

 

     (i) administering to a patient the oral dosage form, the oral
dosage
form comprising:

          minocycline or a pharmaceutically acceptable salt thereof; and

          a controlled release carrier that comprises a fast dissolving carrier and a
slow dissolving carrier,

     wherein the fast dissolving carrier has an intragranular fast dissolving carrier, and
an extragranular fast dissolving carrier, said controlled release carrier being present in
the range from about 20% to about 30%, by weight based on the total weight of the oral
dosage form;

     wherein the extragranular fast dissolving carrier and the slow dissolving carrier are
at a weight ratio of 0.3 to about 0.5 of the extragranular fast dissolving carrier to the
slow dissolving carrier, and

     wherein the minocycline or a pharmaceutically acceptable salt thereof is released in a
slow, continuous release in the patient, without an initial load dose, and at a release rate
in gastric fluid that is either about 25% to about 52% within 1 hour, about 53% to about 89%
within 2 hours, and at least 90% within about 4 hours, or about 30% to about 52% within 1
hour, about 53% to about 84% within 2 hours, and at least 85% within about 4 hours; and

     wherein the oral dosage form administered, once daily, to the patient provides the
patient with about 0.75 mg/kg/day to about 1.5 mg/kg/day of the minocycline or a
pharmaceutically acceptable salt thereof that is effective to treat the acne with a reduced
incidence of at least one adverse effect; and

     (ii) providing information to the patient, which information
comprises

results of performed clinical trials including a comparison of the oral dosage form to
placebo with respect to an aspect of the at least one adverse effect.

     28. The method of Claim 27, wherein the weight ratio of extragranular fast dissolving carrier
to slow dissolving carrier is 0.35 to 0.45.

     29. The method of Claim 27, wherein the weight ratio of extragranular fast dissolving carrier
to slow dissolving carrier is 0.36 to 0.40.

     30. The method of Claim 27, wherein said intragranular fast dissolving carrier
and said slow dissolving carrier are each in an amount greater than said extragranular fast
dissolving carrier.

C-50

 

     31. The method of Claim 27, wherein the at least one adverse effect is selected from the group
consisting of one or more: headache, fatigue, dizziness, pruritus, malaise, mood alteration,
somnolence, urticaria, tinnitus, vertigo, dry mouth, and myalgia.

     32. The method of Claim 27, wherein the about 0.75 mg/kg/day to about 1.5 mg/kg/day is about
1.0 mg/kg/day of the minocycline or a pharmaceutically acceptable salt thereof.

     33. The method of claim 32, wherein the oral dosage form is selected from the group consisting
of 45mg, 90mg, and 135 mg oral dosage forms.

     34. The method of Claim 27, wherein the controlled release carrier releases the minocycline or
a pharmaceutically acceptable salt thereof so that the minocycline or a pharmaceutically acceptable
salt thereof reaches Cmax in a person’s blood from about 3.2 hours to about 4.5 hours
after administration.

     35. The method of Claim 27, wherein the acne is selected from the group consisting of acne
vulgaris, acne rosacea, acne conglobata, acne fulminans, gram—negative folliculitis, and pyoderma
faciale.

     36. A method of administering an oral dosage form for the treatment of acne comprising:

     selecting an oral dosage form from amongst at least 45mg, 90mg and 135mg dosage forms,
the oral dosage form having

          an amount of minocycline;

          a matrix-forming polymer, the matrix-forming polymer being present in the
range between 20% to 30% by weight based on the total weight of the oral
dosage form;

          an intragranular lactose monohydrate; and

          an extragranular lactose monohydrate;

     administering to a patient the oral dosage form once daily, wherein the patient is
provided with about 0.75 mg/kg to 1.5 mg/kg of the minocycline in a slow, continuous
fashion, without an initial load dose, that effectively treats acne of the patient and with
a reduction in adverse vestibular side effects by the once daily administration of the oral
dosage form.

     37. The method of Claim 36, further comprising instructions for administering the oral dosage
form.

C-51

 

     38. The method of Claim 36, wherein the matrix-forming polymer is hydroxypropyl
methylcellulose.

     39. The method of Claim 38, wherein the hydroxypropyl methylcellulose is present in an amount
of 108 mg for the 45mg and the 90 mg oral dosage forms, and present in an amount of 94 mg for the
135 mg oral dosage form.

     40. The method of Claim 38, wherein the hydroxypropyl methylcellulose is present in an amount
about 26% to about 28% by weight based on the total weight of the oral dosage form when the oral
dosage form is 45 mg or 90 mg.

     41. The method of Claim 38, wherein the hydroxypropyl methylcellulose is present in an amount
about 22% to less than 25% by weight based on the total weight of the oral dosage form when the
oral dosage form is in an amount of 135 mg.

     42. The method of Claim 36, wherein the weight ratio of extragranular lactose monohydrate to
the matrix-forming polymer has a weight ratio of 0.35 to 0.45.

     43. The method of Claim 36, wherein when the oral dosage form is 45mg, the matrix-forming
polymer is present in an amount of 108 mg, the intragranular lactose is present in an amount of 197
mg, and the extragranular lactose monohydrate is present in an amount of 41 mg, and wherein the
oral dosage form provides a patient with about 1 mg/kg of the minocycline.

     44. The method of Claim 36, wherein when the oral dosage form is 135mg, the matrix-forming polymer
is present in an amount of 94 mg, the intragranular lactose is present in an amount of 121 mg, and
the extragranular lactose monohydrate is present in an amount of 41 mg, and wherein the oral dosage
form provides a patient with about 1 mg/kg of the minocycline.

C-52

 

EXHIBIT D

Joint Dismissal Agreement

United States Court of Appeals for the Federal Circuit

2008-1373

IMPAX LABORATORIES, INC.,

Plaintiff-Appellant,

v.

MEDICIS PHARMACEUTICAL CORPORATION,

Defendant-Appellee.

Appeal from the United States District Court for the Northern District of California

in Case No. 08-CV-0253, Judge Maxine M. Chesney

JOINT DISMISSAL AGREEMENT

     Plaintiff-Appellant Impax Laboratories, Inc. and Defendant-Appellee Medicis Pharmaceutical
Corporation stipulate to a voluntary dismissal of this appeal with prejudice under Federal Rule of
Appellate Procedure 42(b) in view of the signed and effective License and Settlement Agreement
effecting a settlement of the dispute. Each party shall bear its own costs and attorneys’ fees.

D-1

 

     A proposed order of this Court is attached.

	 	 	 	 	 	 	 	 
	 	 	  
	 	 	 	Respectfully submitted, 
	 
	Date: 	 	  
	 	 	 	  
	 
	 	

Ron E. Shulman

Roger J. Chin

Jennifer Koh

Wilson Sonsini Goodrich & Rosati

650 Page Mill Road

Palo Alto, California 94304

(650) 493-9300

Attorneys for Plaintiff-Appellant

Impax Laboratories, Inc.

 	 
	 	 	
Matthew D. Powers

Weil Gotshal & Manges LLP

201 Redwood Shores Parkway

Redwood Shores, California 94065 	 	 	 
	 	
Elizabeth Stotland Weiswasser

David Greenbaum

Peter Sandel

Jennifer H. Wu

Weil Gotshal & Manges LLP

767 Fifth Avenue

New York, New York 10153

(212) 310-8000

Attorneys for Defendant-Appellee

Medicis Pharmaceutical Corp.

  	 
	 

D-2

 

United States Court of Appeals for the Federal Circuit

2008-1373

IMPAX LABORATORIES, INC.,

Plaintiff-Appellant,

v.

MEDICIS PHARMACEUTICAL CORPORATION,

Defendant-Appellee.

Appeal from the United States District Court for the Northern District of California

in Case No. 08-CV-0253, Judge Maxine M. Chesney

ORDER

     Upon consideration of the Joint Dismissal Agreement filed by the Parties to this Appeal,

IT IS ORDERED THAT:

     (1) The Appeal is DISMISSED with prejudice under Federal Rule of Appellate
Procedure 42(b).

     (2) Each side shall bear their own costs.

	 	 	 	 
	 

	 	FOR THE COURT

	 
	 
	 	 	 
	 

	 	 	 
	Date

	 	Jan Horbaly

Clerk	 

cc: Ron E. Shulman, Esq.

      Matthew D. Powers, Esq.

D-1exhibit10_1.htm

    Exhibit 10.1

     

    
      Performance
Share Unit

      Award
Agreement

       

      Ameren
Corporation

       

      2006
Omnibus Incentive Compensation Plan

       

      March 2,
2009

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      Ameren
Corporation

       

      Performance
Share Unit Award Agreement

       

      THIS
AGREEMENT, effective March 2, 2009, represents the grant of Performance Share
Units by Ameren Corporation (the “Company”), to the Participant named below,
pursuant to the provisions of the Ameren Corporation 2006 Omnibus Incentive
Compensation Plan (the “Plan”).  The number of Shares ultimately
earned and paid, if any, for such Performance Share Units will be determined
pursuant to Section 3 of this Agreement.

       

      The Plan
provides a complete description of the terms and conditions governing the
Performance Share Units.  If there is any inconsistency between the
terms of this Agreement and the terms of the Plan, the Plan’s terms will
completely supersede and replace the conflicting terms of this
Agreement.  All capitalized terms will have the meanings ascribed to
them in the Plan, unless specifically set forth otherwise herein.  The
parties hereto agree as follows:

       

      1.          Grant
Information.  The individual named below has been selected to
be a Participant in the Plan, as specified below:

       

      (a)                 Participant:

       

      (b)                 Target Number of Performance Share
Units:

       

      2.          Performance
Period.  The performance period begins on January 1, 2009, and
ends on December 31, 2011 (“Performance Period”).

       

      3.          Performance
Grid.  The number of Performance Share Units earned by the
Participant under this Agreement will be determined in accordance with the
following grid.  If the actual performance results fall between two of
the categories listed below, straight-line interpolation will be used to
determine the amount earned.  Payouts that otherwise would have been
more than 100% of Target will be capped at Target if the Company’s total
shareholder return (“TSR”) is negative over the three-year
period.  TSR shall be calculated in the manner set forth in Exhibit 1
hereto and compared to the peer group identified in Exhibit 1.

       

      
        	 	 
	
                Ameren’s
      Percentile in

                Total
      Shareholder Return vs.  Utility Peers

                During
      the Performance Period

                 

              	
                Payout—Percent
      of Target

                Performance
      Share Units Granted

                 

                 

              
	
                90th
      percentile +

              	
                200%

              
	
                70th
      percentile

              	
                150%

              
	
                50th
      percentile

              	
                100%

              
	
                30th
      percentile

              	
                50%

              
	
                <30th
      percentile but Earnings Per Share in each year of 

                 
      the Performance Period is $2.54 or greater

              	
                30%

              
	
                <30th
      percentile and Earnings Per Share in each year of 

                         
      the Performance Period is not $2.54 or greater

              	
                0%
      (no payout)

              
	 	 

      

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      4.          Calculation of Earned Performance
Share Units.  The Committee, in its sole discretion, will
determine the number of Performance Share Units earned by the Participant at the
end of the Performance Period based on the performance of the Company,
calculated using the performance grid set forth in Section 3 of this
Agreement.

       

      5.          Vesting of Performance Share
Units.  Subject to provisions set forth in Section 9 of this
Agreement related to a Change of Control (as defined in the Second Amended and
Restated Ameren Corporation Change of Control Severance Plan (“the Change of
Control Severance Plan”)) of the Company and Section 10 relating to termination
for Cause (as defined in the Change of Control Severance Plan), the Performance
Share Units will vest as set forth below:

       

      
        	
                 
      

              	
                (a)

              	
                Provided
      the Participant has continued employment through such date, one hundred
      percent (100%) of the earned Performance Share Units will vest on December
      31, 2011; or

              

      

       

      
        	
                 
      

              	
                (b)

              	
                Provided
      the Participant has continued employment through the date of his death and
      such death occurs prior to December 31, 2011, the Participant will be
      entitled to a prorated award based on the Target Number of Performance
      Share Units set forth in Section 1(b) of this Agreement plus accrued
      dividends as of the date of his death, with such prorated number based
      upon the total number of days the Participant worked during the
      Performance Period; or

              

      

       

      
        	
                 
      

              	
                (c)

              	
                Provided
      the Participant has continued employment through the date of his
      Disability (as defined in Code Section 409A), and such Disability occurs
      prior to December 31, 2011, one hundred percent (100%) of the Performance
      Share Units he would have earned had he remained employed by the Company
      for the entire Performance Period will vest on December 31, 2011;
      or

              

      

       

      
        	
                 
      

              	
                (d)

              	
                Provided
      the Participant has continued employment through the date of retirement
      (as described below) and such retirement occurs before December 31, 2011,
      the following vesting schedule shall be applicable to the Performance
      Share Units:

              

      

       

      
        	
                 
      

              	
                 (i)

              	
                If
      the Participant retires at an age of 55 to 61 with five (5) years of
      service— the Participant is entitled to receive a prorated portion of the
      Performance Share Units that would have been earned had the Participant
      remained employed by the Company for the entire Performance Period, based
      on the actual performance of the Company during the entire Performance
      Period, with the prorated number based upon the total number of days the
      Participant worked during the Performance Period;
  or

              

      

       

      
        	
                 
      

              	
                 (ii)

              	
                If
      the Participant retires after reaching age 62 with five (5) years of
      service— the Participant is entitled to receive one hundred percent (100%)
      of the Performance Share Units that would have been earned had the
      Participant remained employed by the Company for the entire Performance
      Period based on the actual performance of the Company during the entire
      Performance Period.

              

      

       

       

      
        
          
          

        

        
          -2-

          
            

          

        

        
          
          

        

      

       

      Termination
of employment during the Performance Period for any reason other than death,
Disability, retirement as described above, or on or after a Change of Control in
accordance with Section 9 will require forfeiture of this entire award, with no
payment to the Participant.

       

      6.          Form and Timing of
Payment.  All payments of vested Performance Share Units
pursuant to this Agreement will be made in the form of Shares.  Except
as otherwise provided in this Agreement, payment will be made upon the earliest
to occur of the following:

       

      
        	
                 
      

              	
                (a)

              	
                January
      1, 2012 or as soon as practicable
thereafter;

              

      

       

      
        	
                 
      

              	
                (b)

              	
                The
      Participant’s death or as soon as practicable
  thereafter.

              

      

       

      7.          Right as
Shareholder.  Except as specifically set forth in this
Agreement, the Participant shall not have voting or any other rights as a
shareholder of the Company with respect to Performance Share
Units.  The Participant will obtain full voting and other rights as a
shareholder of the Company upon the payment of the Performance Share Units in
Shares as provided in Section 6 or 9.

       

      8.          Dividends.  The
Participant shall be entitled to receive dividend equivalents, which represent
the right to receive Shares measured by the dividend payable with respect to the
corresponding number of Performance Share Units.  Dividend equivalents
on Performance Share Units will accrue and be reinvested into additional
Performance Share Units throughout the three-year Performance
Period.  The additional Shares will be paid as set forth in Section 6
or 9 of this Agreement.

       

      9.          Change of
Control.

       

      (a)          Company No Longer
Exists.  Upon a Change of Control which occurs on or before
December 31, 2011 in which the Company ceases to exist or is no longer publicly
traded on the New York Stock Exchange or the NASDAQ Stock Market, the Target
Number of Performance Share Units awarded as set forth in Section 1(b) of this
Agreement plus the accrued dividends as of the date of the Change of Control
shall be converted to nonqualified deferred compensation with the following
features:

       

      
        	
                 
      

              	
                 
      (i)

              	
                The
      initial amount of the nonqualified deferred compensation shall equal the
      value of one Share based on the closing price on the New York Stock
      Exchange on the last trading day prior to the date of the Change of
      Control multiplied by the sum of the Target Number of Performance Share
      Units awarded as set forth in section 1(b) of this Agreement plus the
      additional Performance Share Units attributable to accrued
      dividends;

              

      

       

      
        	
                 
      

              	
                 
      (ii)

              	
                Interest
      on the nonqualified deferred compensation shall accrue based on the prime
      rate (adjusted on the first day of each calendar quarter) as published in
      the “Money Rates” section in the Wall Street Journal
      from the date of the Change of Control until such nonqualified
      deferred compensation is distributed or
  forfeited;

              

      

       

      
        	
                 
      

              	
                 
      (iii)

              	
                If
      the Participant remains employed with the Company or its successor until
      the last day of the Performance Period, the nonqualified deferred
      compensation, plus 

              

      

       

       

      
        
          
          

        

        
          -3-

          
            

          

        

        
          
          

        

      

       

      interest, shall be paid to the Participant in an immediate lump
sum on January 1, 2012, or as soon as practicable thereafter.

       

      
        	
                 
      

              	
                 
      (iv)

              	
                If
      the Participant remains employed with the Company or its successor until
      his death or Disability which occurs before the last day of the
      Performance Period, the Participant (or his estate or designated
      beneficiary) shall immediately receive the nonqualified deferred
      compensation, plus interest, upon such death or
  Disability;

              

      

       

      
        	
                 
      

              	
                 
      (v)

              	
                If
      the Participant has a qualifying termination (as defined in Section 9(c))
      before the last day of the Performance Period, the Participant shall
      immediately receive the nonqualified deferred compensation, plus interest,
      upon such termination; provided that such distribution shall be deferred
      until the date which is six months following the Participant’s termination
      of employment to the extent required by Code Section 409A;
    and

              

      

       

      
        	
                 
      

              	
                 
      (vi)

              	
                In
      the event the Participant terminates employment before the end of the
      Performance Period for any reason other than described in Sections (iv) or
      (v) above, the nonqualified deferred compensation, plus interest, will
      immediately be forfeited.

              

      

       

      (b)          Company Continues to
Exist.  If there is a Change of Control of the Company but the
Company continues in existence and remains a publicly traded company on the New
York Stock Exchange or the NASDAQ Stock Market, the Performance Share Units will
pay out upon the earliest to occur of the following:

       

      
        	
                 
      

              	
                 
      (i)

              	
                As
      set forth in Section 6 (“Form and Timing of Payments”) of this Agreement;
      or

              

      

       

      
        	
                 
      

              	
                 
      (ii)

              	
                If
      the Participant experiences a qualifying termination (as defined in
      Section 9(c)) during the two-year period following the Change of Control
      and the termination occurs prior to January 1, 2012, one hundred percent
      (100%) of the Performance Share Units he would have earned had he remained
      employed for the entire Performance Period will vest on December 31, 2011
      and the vested Performance Share Units will be paid in Shares on January
      1, 2012 or as soon as practicable
thereafter.

              

      

       

      (c)          Qualifying
Termination.  For purposes of Sections 9(a)(v) and 9(b)(ii), a
qualifying termination means (i) an involuntary termination without Cause, (ii)
for Change of Control Severance Plan participants, a voluntary termination of
employment for Good Reason (as defined in the Change of Control Severance Plan)
or (iii) a voluntary termination that qualifies for severance under the Ameren
Corporation Severance Plan for Management Employees (as in effect immediately
prior to the Change of Control).

       

      (d)          Termination in Anticipation
of Change of Control.  If a Participant qualifies for benefits
as provided in the last sentence of Section 4.1 of the Change of Control
Severance Plan, or if a Participant is not a Participant in the Change of
Control Severance Plan but is terminated within six (6) months prior to the
Change of Control and qualifies for severance benefits under the Company’s
general severance plan and the Participant’s termination of employment occurs
before December 31, 2011, then the Participant shall receive (i) upon a
Change of Control described in Section 9(a), an 

       

       

      
        
          
          

        

        
          -4-

          
            

          

        

        
          
          

        

      

       

      immediate
cash payout equal to the value of one Share based on the closing price on the
New York Stock Exchange on the last trading day prior to the date of the Change
of Control multiplied by the sum of the Target Number of Performance Share Units
awarded as set forth in Section 1(b) of this Agreement plus the additional
Performance Share Units attributable to accrued dividends or (ii) upon a Change
of Control described in Section 9(b), the payout provided for in Section
9(b).

       

      10.          Termination for
Cause.  Termination of employment for Cause at any time prior
to payout of the Shares will require forfeiture of the entire Performance Share
Unit Award, with no distribution of any Shares to the Participant.

       

      11.          Nontransferability.  Performance
Share Units awarded pursuant to this Agreement may not be sold, transferred,
pledged, assigned or otherwise alienated or hypothecated (a “Transfer”) other
than by will or by the laws of descent and distribution, except as provided in
the Plan.  If any Transfer, whether voluntary or involuntary, of
Performance Share Units is made, or if any attachment, execution, garnishment,
or lien will be issued against or placed upon the Performance Share Units, the
Participant’s right to such Performance Share Units will be immediately
forfeited to the Company, and this Agreement will lapse.

       

      12.          Requirements of
Law.  The granting of Performance Share Units under the Plan
will be subject to all applicable laws, rules, and regulations, and to such
approvals by any governmental agencies or national securities exchanges as may
be required.

       

      13.          Tax
Withholding.  The Company will have the power and the right to
deduct or withhold, or require the Participant or the Participant’s beneficiary
to remit to the Company, an amount sufficient to satisfy federal, state, and
local taxes, domestic or foreign, required by law or regulation to be withheld
with respect to any taxable event arising as a result of this
Agreement.

       

      14.          Stock
Withholding.  With respect to withholding required upon any
taxable event arising as a result of Performance Share Units granted hereunder,
the Company, unless notified otherwise by the Participant in writing within
thirty (30) days prior to the taxable event, will satisfy the tax withholding
requirement by withholding Shares having a Fair Market Value equal to the total
minimum statutory tax required to be withheld on the transaction.  The
Participant agrees to pay to the Company, its Affiliates, and/or its
Subsidiaries any amount of tax that the Company, its Affiliates, and/or its
Subsidiaries may be required to withhold as a result of the Participant’s
participation in the Plan that cannot be satisfied by the means previously
described.

       

      15.          Administration.  This
Agreement and the Participant’s rights hereunder are subject to all the terms
and conditions of the Plan, as the same may be amended from time to time, as
well as to such rules and regulations as the Committee may adopt for
administration of the Plan.  It is expressly understood that the
Committee is authorized to administer, construe, and make all determinations
necessary or appropriate to the administration of the Plan and this Agreement,
all of which will be binding upon the Participant.

       

      16.          Continuation of
Employment.  This Agreement will not confer upon the
Participant any right to continuation of employment by the Company, its
Affiliates, and/or its Subsidiaries, nor will this Agreement interfere in any
way with the Company’s, its Affiliates’, and/or its Subsidiaries’ right to
terminate the Participant’s employment at any time.

       

       

      
        
          
          

        

        
          -5-

          
            

          

        

        
          
          

        

      

       

      17.          Amendment to the
Plan.  The Plan is discretionary in nature and the Committee
may terminate, amend, or modify the Plan; provided, however, that no such
termination, amendment, or modification of the Plan may in any way adversely
affect the Participant’s rights under this Agreement, without the Participant’s
written approval.

       

      18.          Amendment to this
Agreement.  The Company may amend this Agreement in any manner,
provided that no such amendment may adversely affect the Participant’s rights
hereunder without the Participant’s written approval.

       

      19.          Successor.  All
obligations of the Company under the Plan and this Agreement, with respect to
the Performance Share Units, will be binding on any successor to the Company,
whether the existence of such successor is the result of a direct or indirect
purchase, merger, consolidation, or otherwise, of all or substan­tially all
of the business and/or assets of the Company.

       

      20.          Severability.  The
provisions of this Agreement are severable and if any one or more provisions are
determined to be illegal or otherwise unenforceable, in whole or in part, the
remaining provisions will nevertheless be binding and enforceable.

       

      21.          Applicable Laws and Consent to
Jurisdiction.  The validity, construction, interpretation, and
enforceability of this Agreement will be determined and governed by the laws of
the State of Missouri without giving effect to the principles of conflicts of
law.  For the purpose of litigating any dispute that arises under this
Agreement, the parties hereby consent to exclusive jurisdiction and agree that
such litigation will be conducted in the federal or state courts of the State of
Missouri.

       

      IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed effective
as of March 2, 2009.

       

         
Ameren Corporation

       

      

             

             Senior
Vice President and Chief

             Human
Resources Officer—

      
 

      By:__________________________________

      Participant

       

      

       

      
        
          
          

        

        
          -6-

          
            

          

        

        
          
          

        

      

      

      EXHIBIT
1

       

      

      Total
Shareholder Return

      Total
Shareholder Return shall be calculated as follows:

      

       

      

       

      *In
practice, dividends will be treated as having been reinvested
quarterly.

      

      

      Peer
Group

      Following
are the peer group companies.  In order to be counted in the final
calculations, a company must still have a ticker at the end of the performance
period.

      

      
        	
                Company

                 

              	
                Ticker

              	
                Company

              	
                Ticker

              
	
                AMERICAN
      ELECTRIC POWER CO

              	
                AEP

              	
                NORTHEAST
      UTILITIES

              	
                NU

              
	
                ALLIANT
      ENERGY CORPORATION

              	
                LNT

              	
                NSTAR

              	
                NST

              
	
                CONSOLIDATED
      EDISON INC

              	
                ED

              	
                OGE
      ENERGY

              	
                OGE

              
	
                DOMINION
      RESOURCES INC

              	
                D

              	
                PEPCO
      HOLDINGS INC

              	
                POM

              
	
                DTE
      ENERGY CO

              	
                DTE

              	
                PINNACLE
      WEST CAPITAL CORP

              	
                PNW

              
	
                DUKE
      ENERGY

              	
                DUK

              	
                PROGRESS
      ENERGY

              	
                PGN

              
	
                EDISON
      INTERNATIONAL

              	
                EIX

              	
                SCANA

              	
                SCG

              
	
                FIRSTENERGY
      CORP

              	
                FE

              	
                SOUTHERN
      CO

              	
                SO

              
	
                FPL
      GROUP INC

              	
                FPL

              	
                WESTAR
      ENERGY, INC.

              	
                WR

              
	
                GREAT
      PLAINS ENERGY INC

              	
                GXP

              	
                WISCONSIN
      ENERGY

              	
                WEC

              
	
                INTEGRYS

              	
                TEG

              	
                XCEL
      ENERGY INC

              	
                XEL

              

      

      
-7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}]]